ECAP: The Neurocognitive Architecture of Endocannabinoid-Associated Pathways

A Systems Neuroscience Model for Cannabinoid Action

Author: Dr. Jeff Bullock

Date: May 2025

PRISM AI Consultants

Email: info@prismaiconsultants.com

Executive Summary

The Endocannabinoid-Associated Pathways (ECAP) model offers a potentially transformative understanding of Cannabis sativa's complex effects, aiming to move beyond the traditional Endocannabinoid System (ECS). This white paper elucidates the ECAP framework, its scientific underpinnings, and its proposed implications for research, clinical practice, and innovation, while acknowledging areas requiring further empirical validation.

- **Expanded Conceptual Framework:** ECAP positions the ECS as a central hub within a broader molecular network. This integrated system includes non-canonical receptors (e.g., TRPV1, GPR55, PPARs), major neurotransmitter systems, hormonal axes (e.g., HPA, oxytocin), and the gut-brain-immune axis, offering a more holistic view of cannabinoid influence.
- **Mechanistic Synergies & Risk Mitigation:** ECAP seeks to explain chemovar-specific effects and individual variability. This includes differential efficacy and the potential for adverse responses, which ECAP aims to help predict and mitigate through informed chemovar selection, personalized dosing strategies, and an understanding of synergistic interactions across molecular targets.
- **Implications for Practice and Optimization (with caveats):** ECAP supports the development of personalized cannabinoid therapies by addressing root dysfunctions in neuropsychiatric, neurodegenerative, and inflammatory conditions. It also provides a hypothesized mechanistic lens for optimizing Creativity, Action, and Performance (CAP), emphasizing that this application requires substantial research and careful consideration of individual risk profiles and dose-response relationships.
- **Scientific Advancement & Responsible Commercial Innovation:** ECAP promotes hypothesis-driven research and data-backed formulation strategies. The goal is to foster consistent, targeted cannabis-based therapeutics and wellness products, developed with a strong evidence base and a commitment to safety.

Ultimately, ECAP aims to make cannabinoid science more model-driven and precision-oriented. By providing a more complete, albeit evolving, understanding of cannabis's complex biological interactions, ECAP endeavors to responsibly shape the future of cannabis-based healthcare and neurocognitive innovation.

Introduction

The study of Cannabis sativa has evolved dramatically, largely due to the discovery of the endocannabinoid system (ECS) (Zou & Kumar, 2018). While the traditional ECS—centered on CB1 and CB2 receptors—has been foundational, it is increasingly recognized that it does not fully account for the vast physiological and cognitive complexity observed with cannabis use. This white paper introduces the Endocannabinoid-Associated Pathways (ECAP) model as a more integrative and comprehensive framework (Pertwee, 2008). ECAP aims to provide a deeper understanding of cannabis's multifaceted actions, acknowledging that while this model is ambitious, ongoing research is essential to fully elucidate all its proposed interactions and validate its predictive capabilities.

Key terms used throughout this paper are defined in the Glossary at the end.

Furthermore, this white paper explores how the ECAP model may provide a theoretical basis for modulating the neurocognitive architecture underpinning human Creativity, Action, and Performance (CAP). This application, an area of growing interest in both clinical and performance domains, is presented as a hypothesized extension of the ECAP framework. Its validity and potential benefits require dedicated empirical investigation, with careful consideration of individual variability, potential risks, and the necessity for precise, context-specific application

1.1. The Limitations of the Traditional ECS Model

The ECS, while central, is insufficient on its own to explain the diverse effects stemming from the interaction of over 100 phytocannabinoids and more than 200 terpenes found in Cannabis sativa. Many observed effects occur independent of direct CB1 and CB2 receptor activity, strongly suggesting the involvement of a broader network of additional molecular targets. This gap highlights the need for a more encompassing model to guide research and application.

1.2. Defining ECAP: An Integrated Network Model

ECAP proposes an integrated network model that positions the canonical cannabinoid receptors (CB1, CB2) within a wider array of interacting systems. This includes non-canonical targets (e.g., TRPV1, GPR55, PPARs), major neurotransmitter systems (dopamine, serotonin, GABA, glutamate), hormonal pathways (e.g., HPA axis, oxytocin), and gut-brain-immune interactions. Within this framework, the "entourage effect," often described as the synergistic interaction between various cannabis compounds, is recontextualized as a product of these multi-target engagements across the ECAP network. (see Figure 1 Entourage Effect Model below)



Figure 1: Entourage Effect Model

Caption: The entourage effect arises from multi-target interactions of cannabinoids (e.g., THC, CBD) and terpenes (e.g., linalool, β-caryophyllene) across ECAP nodes, producing synergistic outcomes like enhanced relaxation (Russo, 2011; Ferber et al., 2020).
https://www.canva.com/design/DAGoEPDPwC8/jnRaNNniOvD0oN-LqdHENQ/view?utm_content=DAGoEPDPwC8&utm_campaign=designshare&utm_medium=link2&utm_source=uniquelinks&utlId=hccca4cb0a4

Instead of a vague notion of general synergy, ECAP provides a mechanistic framework suggesting these synergies emerge from complex interactions across multiple, distinct, yet interconnected pathways (Russo, 2011; Ben-Shabat et al., 1998). For example, a terpene might primarily target a TRP channel or a serotonin receptor, while a phytocannabinoid simultaneously modulates CB1 receptor activity. The downstream effects of these parallel activations can converge on shared signaling molecules, neural circuits, or physiological processes, leading to an overall effect that is different from, and often greater than, the sum of the individual actions. This network-level perspective moves beyond simple receptor affinity arguments and offers testable hypotheses regarding specific compound combinations, which are critical for developing targeted and predictable interventions. (See Figure 2 for a conceptual map of ECAP network interactions).



Figure 2: ECAP Network Diagram

Caption: Conceptual overview of the Endocannabinoid-Associated Pathways (ECAP) model, illustrating the central role of the ECS (CB1, CB2) and its interactions with non-canonical receptors (e.g., TRPV1, GPR55, PPARs), neurotransmitter systems (dopamine, serotonin, GABA, glutamate), hormonal axes (HPA, oxytocin), and the gut-brain-immune axis. Phytocannabinoids and terpenes are shown to act on multiple nodes within this interconnected network (Russo, 2011).

https://www.canva.com/design/DAGn_8KyjHc/UE-DdBpzKL318jkPhlaz8w/view?utm_content=DAGn_8KyjHc&utm_campaign=designshare&utm_medium=link2&utm_source=uniquelinks&utlId=ha581d17aa4

1.3. Scope and Significance

The ECAP model repositions cannabis as a systems-level modulator, not merely a psychoactive agent. It highlights the critical role of individual neurobiology in determining response variability and lays the foundation for targeted, personalized interventions in both medical and high-performance contexts. Furthermore, by elucidating these complex interactions, ECAP not only supports targeted interventions but also offers a more nuanced understanding of individual variability in response. This includes a framework for anticipating and potentially mitigating adverse effects that can occur under certain conditions or in susceptible individuals,

underscoring the importance of a balanced risk-benefit assessment in any application.

This expanded framework challenges simplistic views of cannabis effects. It underscores how varying concentrations of diverse phytochemicals can differentially engage numerous pathways, leading to a wide spectrum of outcomes. Such a nuanced perspective is crucial for advancing personalized medicine approaches in cannabinoid therapeutics and for responsibly harnessing cannabis's potential while prioritizing safety and efficacy.

Core Cannabinoid Receptors in ECAP

While ECAP expands beyond the traditional ECS, the CB1 and CB2 receptors remain foundational pillars of this integrated network. Their distinct distributions, signaling mechanisms, and physiological roles are critical to understanding how cannabis constituents initiate many of their effects (Pertwee, 2008). These receptors act as primary gateways for many endocannabinoids and phytocannabinoids, triggering cascades of intracellular events that propagate throughout the ECAP network, interacting with and influencing the other systems ECAP incorporates (Ibeas Bih et al., 2015).

2.1. CB1 Receptors: Neurocognitive and Physiological Roles

CB1 receptors are among the most abundantly expressed G protein-coupled receptors (GPCRs) in the mammalian brain. They exhibit particularly high densities in regions crucial for cognitive and motor functions, such as the hippocampus, cortex, basal ganglia, cerebellum, amygdala, and hypothalamus (Zou & Kumar, 2018). Beyond the Central Nervous System (CNS), CB1 receptors are also found in various peripheral tissues, contributing to energy metabolism and other physiological processes, the full extent of which ECAP seeks to integrate into a broader systemic understanding.

Signaling through CB1 receptors is primarily coupled to Gi/o proteins. Upon activation by agonists like anandamide, 2-AG, or THC, these receptors inhibit adenylyl cyclase, modulate ion channels, and reduce neurotransmitter release—particularly GABA and glutamate (Bisogno et al., 2001). This regulation is central to synaptic plasticity, learning, memory, and emotional processing. The diverse downstream consequences of these actions, especially when considering co-activation of other ECAP targets, are key to understanding both therapeutic potentials and potential adverse effects of cannabis.

CB1’s retrograde signaling allows for dynamic, moment-to-moment regulation of synaptic strength, underlying processes like depolarization-induced suppression of excitation/inhibition (DSE/DSI) and long-term depression. CB1’s biased agonism further highlights how different cannabinoids can selectively activate downstream

pathways, producing divergent effects even with shared receptor targets (Ibeas Bih et al., 2015). ECAP emphasizes that these nuanced signaling properties are critical for explaining chemovar-specific outcomes.

2.2. CB2 Receptors: Immune Modulation and Neuroinflammation

CB2 receptors, while initially thought to be restricted to immune tissues, are now known to be inducibly expressed in the brain, particularly under pathological conditions. They are primarily involved in regulating immune responses, inflammation, and neuroprotection. Within the ECAP model, the interplay between central and peripheral CB2 activity is considered vital for systemic homeostasis.

Activation of CB2 receptors inhibits pro-inflammatory cytokines, modulates immune cell migration, and promotes tissue healing. Their expression is upregulated in disease states like multiple sclerosis, Alzheimer’s disease, and chronic pain, making CB2 an attractive target for neuroimmune modulation. ECAP provides a framework for understanding how CB2 modulation can be optimized in conjunction with other pathways for enhanced therapeutic benefit.

Cannabinoids like β-caryophyllene (a terpene) act as CB2 agonists, while others like CBD influence CB2-associated pathways through various direct and indirect mechanisms. Within ECAP, CB2 signaling links peripheral immune modulation with central neuroinflammation, positioning it as a key node in the gut-brain-immune interface, a nexus critical for many of the systemic conditions ECAP addresses.

Expanding the Receptor Landscape: Non-Canonical ECAP Targets

The ECAP model significantly expands beyond CB1 and CB2 to include several "non-canonical" receptors and ion channels that interact with cannabinoids and play vital roles in cannabis pharmacology. These targets provide a more complete and nuanced understanding of how cannabis exerts its wide-ranging effects, contributing to the complex interplay of therapeutic benefits and potential adverse responses that ECAP seeks to delineate (Pertwee, 2008; Russo, 2011).

3.1. TRPV1 Channels: Pain, Inflammation, and Sensory Regulation

Transient receptor potential vanilloid type 1 (TRPV1) channels are non-selective cation channels that act as polymodal sensors, activated by heat, acidity, and ligands like capsaicin, anandamide, and several cannabinoids (CBD, CBG, CBDV). Activation leads to calcium influx, which triggers downstream pathways that modulate pain, anxiety, and inflammation. Within ECAP, TRPV1 modulation is considered a key mechanism for the analgesic and anxiolytic properties of certain chemovars, but also a potential contributor to sensory alterations if over-activated or

dysregulated in conjunction with other targets. (See Figure 3 for a simplified representation of TRPV1 signaling, alongside CB1 signaling for context).

Figure 3: Receptor Signaling Pathways

Panel A: CB1 Signaling



References: Howlett, 1985; Mackie & Hille, 1992; Wilson & Nicoll, 2001

Panel B: TRPV1 Signaling



References: Caterina et al., 1997; De Petrocellis et al., 2011

Figure 3: Receptor Signaling Pathways A & B

Caption: Simplified representation of key signaling pathways for (A) CB1 receptor (Gi/o coupling, adenylyl cyclase inhibition, ion channel modulation) and (B) TRPV1 channel (cation influx, particularly Ca2+, upon activation by heat, capsaicin, or endovanilloids). (References: Howlett, 1985; Mackie & Hille, 1992; Wilson & Nicoll, 2001; Caterina et al., 1997; De Petrocellis et al., 2011).
https://www.canva.com/design/DAGoD2mX21s/Bt5cBYZ-22aA1jNt_kep2Q/view?utm_content=DAGoD2mX21s&utm_campaign=designshare&utm_medium=link2&utm_source=uniquelinks&utlId=h121fdbea6f

3.2. GPR55: Excitability, Inflammation, and Metabolism

GPR55 is an orphan GPCR responsive to ligands such as lysophosphatidylinositol (LPI), THC, and CBD (which can act antagonistically in some contexts). It is involved in calcium signaling and RhoA activation, impacting neuronal excitability, bone remodeling, and immune regulation.

Though its classification remains somewhat controversial, GPR55 is expressed in the brain, adrenal glands, and GI tract. ECAP incorporates GPR55 for its contribution to excitatory tone, inflammation, and energy homeostasis. Its role is particularly relevant in neuropsychiatric and metabolic disorders, where dysregulation of GPR55 signaling could contribute to pathology or, conversely, offer a target for therapeutic modulation alongside other ECAP components.

3.3. PPARs: Nuclear Receptors and Genomic Modulation

Peroxisome proliferator-activated receptors (PPARα, δ, and γ) are nuclear transcription factors activated by cannabinoids like CBD, THC, and AEA. PPARγ activation, in particular, is linked to anti-inflammatory and neuroprotective effects, insulin sensitivity, and lipid regulation (Ibeas Bih et al., 2015).

Within ECAP, PPARs offer a genomic regulatory layer, connecting cannabinoid signaling with chronic disease modulation and metabolic resilience. This highlights a mechanism through which cannabis constituents can exert long-term adaptive or maladaptive changes, depending on the specific compounds, dosage, and individual context.

3.4. 5-HT3A and Glycine Receptors: Neurotransmission and Sensory Balance

5-HT3A (a serotonin receptor) is a ligand-gated ion channel involved in nausea, mood, and anxiety. THC and CBD modulate this receptor, contributing to anti-emetic and anxiolytic effects. ECAP considers 5-HT3A modulation a critical factor in the therapeutic profile for managing chemotherapy side effects or certain anxiety states, but also a site where THC might, in some contexts, contribute to undesirable mood alterations if not balanced by other constituents.

Glycine receptors (GlyRs), primarily in the brainstem and spinal cord, mediate inhibitory neurotransmission. CBD enhances glycine signaling as an allosteric modulator, supporting analgesic and anti-spasticity effects—key for conditions like multiple sclerosis and chronic pain. The ECAP model integrates GlyR modulation as a significant contributor to the pain-relieving and muscle-relaxant properties of CBD-rich chemovars.

3.5. Voltage-Gated Channels and Functional Modularity

Phytocannabinoids also interact with voltage-gated sodium, potassium, and calcium channels, influencing neuronal excitability and neurotransmitter release independently of CB receptors. These interactions broaden ECAP's relevance to seizure control, neuropathy, and cognitive modulation. This diverse channel modulation underscores the complexity of cannabinoid action; while potentially beneficial for conditions like epilepsy, it also highlights pathways through which cognitive functions could be impacted, positively or negatively, depending on the specific cannabinoid profile and net effect on neuronal firing patterns. (see Table 1: Key Molecular Targets within the ECAP Model below)

Table 1: Key Molecular Targets within the ECAP Model

Target	Type	Key Ligands	Physiological Roles	References
CB1	GPCR (Gi/o)	THC, AEA, 2-AG	Neurotransmitter release, euphoria, memory, appetite	Howlett, 1985; Bloomfield et al., 2016
CB2	GPCR (Gi/o)	THC, β-Caryophyllene	Immune modulation, anti-inflammatory	Munro et al., 1993; Gertsch et al., 2008
TRPV1	Cation Channel	CBD, CBG, Myrcene, AEA	Pain modulation, anxiolysis, inflammation	Caterina et al., 1997; De Petrocellis et al., 2011
GPR55	GPCR (Gq/11, G12/13)	THC, CBD (antagonist), LPI	Neuronal excitability, inflammation, metabolism	Ryberg et al., 2007; Lauckner et al., 2008
PPARs	Nuclear Receptor	CBD, THC, AEA	Anti-inflammatory, neuroprotection, metabolism	O'Sullivan, 2007; O'Sullivan, 2016
5-HT3A	Ion Channel	THC, CBD (inhibitor)	Anti-emetic, anxiolysis	Barann et al., 2002
GlyRs	Chloride Channel	CBD (allosteric modulator)	Analgesia, spasticity reduction	Ahrens et al., 2009

Caption: Key molecular targets in the ECAP model mediate diverse effects of cannabis constituents, from euphoria to anti-inflammatory responses (Pertwee, 2008; Russo, 2011).

Table 1: Key Molecular Targets within the ECAP Model

Caption: Key molecular targets in the ECAP model mediate diverse effects of cannabis constituents, from euphoria to anti-inflammatory responses. Understanding these targets and their interactions is crucial for predicting both therapeutic outcomes and potential adverse effects (Pertwee, 2008; Russo, 2011). https://claude.ai/public/artifacts/ddba8794-293e-427f-97b8-b91145d1ed11

Neurotransmitter System Interactions within ECAP

Cannabinoids profoundly influence neurotransmission through direct and indirect modulation of key systems responsible for cognition, mood, behavior, and memory. The ECAP model captures how cannabis constituents affect dopaminergic, serotonergic, GABAergic, glutamatergic, and cholinergic networks, often through multiple targets and feedback loops. Understanding these complex interactions, as framed by ECAP, is essential for both harnessing therapeutic benefits and managing potential risks.

4.1. Dopaminergic System: Reward, Motivation, and Executive Function

CB1 receptors regulate dopamine (DA) release in the mesolimbic (VTA → nucleus accumbens) and mesocortical (VTA → prefrontal cortex) pathways. THC increases DA in the short term, contributing to euphoria and motivational salience. Chronic overactivation or high-dose exposure, however, can dampen dopamine synthesis and receptor sensitivity, potentially contributing to anhedonia, cognitive flattening, and amotivational states. This highlights a significant risk associated with certain THC-dominant use patterns, which ECAP aims to address through informed chemovar selection and dose management.

CBD, unlike THC, may help normalize dopaminergic tone through indirect effects on FAAH inhibition and serotonin (5-HT1A) receptor activity. This makes CBD a candidate for supporting mood and executive function in high-stress or dopamine-depleted states, potentially by counteracting some of THC's less desirable dopaminergic impacts when present in a balanced formulation.

4.2. Serotonergic System: Mood, Anxiety, and Sleep

CBD is a known agonist at 5-HT1A receptors, contributing to its anxiolytic and antidepressant properties. THC, by contrast, has complex, dose-dependent effects on the serotonergic system: low doses may reduce anxiety, while high doses may heighten it—likely due to disrupted 5-HT signaling or overactivation of CB1 in emotional regulation circuits. This duality is why ECAP emphasizes formulation design: chemovars rich in CBD and calming terpenes (e.g., linalool) may offset THC's volatility and enhance therapeutic consistency. This approach, central to ECAP, aims to mitigate THC-induced anxiety and promote more predictable outcomes by leveraging the synergistic interactions of multiple constituents.

4.3. GABAergic and Glutamatergic Systems: Excitability and Inhibition

CB1 receptors modulate GABA and glutamate release through retrograde signaling. Suppression of these neurotransmitters affects the delicate excitation/inhibition (E/I) balance—a key component of memory, learning, seizure activity, and overall neuronal stability.

Cannabinoids like THC can broadly disrupt this E/I balance, which may contribute to cognitive impairment or, in susceptible individuals, anxiety. Others, like CBD, appear to modulate glutamatergic excitability more selectively, supporting ECAP's application in conditions like epilepsy, and potentially contributing to neuroplasticity and cognitive support. Terpenes like linalool enhance GABAergic tone, contributing to sedative and anxiolytic effects. ECAP posits that achieving a favorable E/I balance through strategic formulation is key to optimizing therapeutic effects while minimizing unwanted CNS disruption.

4.4. Cholinergic Modulation and Cognitive Performance

Acetylcholine (ACh) governs attention, learning, and memory. THC can impair ACh release in the hippocampus and cortex, leading to short-term memory disruption. However, terpenes like α-pinene inhibit acetylcholinesterase, an enzyme that breaks down ACh, thereby preserving ACh levels and potentially counteracting some of THC's cognitive deficits.

This illustrates a key ECAP insight: cognitive effects of cannabis are not solely determined by THC content but by the net effect of how other cannabinoids and terpenes shift the overall neurotransmitter balance. This highlights the potential for rationally designed chemovars to mitigate specific adverse cognitive effects associated with THC.

4.5. Integrated Neurotransmitter Balance

The ECAP framework suggests that the ultimate effects of cannabis emerge from the net vector of neurotransmitter modulation across multiple systems. For instance, a high-THC chemovar may activate CB1 receptors to release dopamine but also suppress glutamate and GABA, potentially leading to anxiety, dysphoria, or cognitive impairment in sensitive users (Devinsky et al., 2017). Understanding these multi-system impacts, as facilitated by ECAP, is crucial not only for optimizing therapeutic outcomes but also for predicting, and potentially minimizing, adverse psychoactive events. This involves moving beyond single-target thinking to a holistic assessment of a chemovar's likely impact on the integrated neurotransmitter network.

Conversely, formulations balanced with CBD, β-caryophyllene, and serotonin-modulating terpenes (like linalool or limonene) can promote a more stable affective and cognitive profile. ECAP allows for predictive insights and

hypothesis-driven formulation strategies based on chemovar profiles and individual user neurobiology, aiming for greater precision and safety in cannabinoid use.

Table 2: Major Neurotransmitter and Hormonal Systems Modulated by ECAP

System	Key Targets	Cannabis Effects	Outcomes	References
Dopaminergic	CB1 (VTA-NAc, PFC)	THC: ↑ DA release; Chronic: ↓ DA synthesis	Euphoria, motivation; Chronic: anhedonia	Bloomfield et al., 2016; Volkow et al., 2014
Serotonergic	5-HT1A (CBD agonist), CB1 (↓ 5-HT)	CBD: Anxiolysis; THC: Dose-dependent anxiety	Mood regulation, sleep	Russo et al., 2005; Garcia-Gutiérrez et al., 2020
GABAergic	CB1 (DSI), GABA-A (terpenes)	THC: Disrupts balance; Linalool: Enhances GABA	Cognitive impairment, sedation	Wilson & Nicoll, 2002; Linck et al., 2010
Glutamatergic	CB1 (DSE)	THC: ↓ Glutamate; CBD: Anti-convulsant	Cognitive effects, seizure control	Chevaleyre et al., 2006; Devinsky et al., 2014
HPA Axis	CB1 (↓ CRH), 5-HT1A	THC: Biphasic cortisol; CBD: ↓ Cortisol	Stress response, anxiety	Hillard et al., 2009; Zuardi et al., 2008
Oxytocin	5-HT1A, CB1	CBD: ↑ OXT; CB1: Modulates OXT	Social bonding, empathy	Wei et al., 2015; Schiavon et al., 2020

Abbreviations: VTA-NAc = Ventral Tegmental Area-Nucleus Accumbens; PFC = Prefrontal Cortex; DA = Dopamine; 5-HT = Serotonin; DSI = Depolarization-induced Suppression of Inhibition; DSE = Depolarization-induced Suppression of Excitation; CRH = Corticotropin-releasing Hormone; OXT = Oxytocin

Caption: ECAP modulates neurotransmitter and hormonal systems, influencing cognition, emotion, and stress responses through multi-target interactions (Bloomfield et al., 2016; Russo, 2011).

Table 2: Major Neurotransmitter and Hormonal Systems Modulated by ECAP

Caption: This table summarizes key neurotransmitter and hormonal systems influenced by cannabis constituents within the ECAP model, outlining primary modulators, effects on the system, and broad behavioral/cognitive implications,

including potential therapeutic targets and areas of risk. Abbreviations: VTA-Nac = Ventral Tegmental Area-Nucleus Accumbens; PFC = Prefrontal Cortex; DA = Dopamine; 5-HT = Serotonin; DSI = Depolarization-induced Suppression of Inhibition; DSE = Depolarization-induced Suppression of Excitation; CRH = Corticotropin-Releasing Hormone; OXT = Oxytocin.
https://claude.ai/public/artifacts/02b062c7-3b95-4f62-b8c0-38c02d011b9b

ECAP and the Neurocognitive Architecture of Creativity, Action, and Performance (CAP)

While the primary focus of the ECAP model is to elucidate the complex therapeutic effects of cannabis, its comprehensive framework also allows for speculative exploration into how cannabis might influence higher-order human capabilities: Creativity, Action, and Performance (CAP). By mapping how phytocannabinoids and terpenes could theoretically influence key pathways within the ECAP network, this section proposes a conceptual paradigm for investigating targeted cannabis formulations for potential neurocognitive optimization.

It is imperative to state that the CAP framework presented here is largely theoretical and requires substantial empirical validation through rigorous, controlled research. While ECAP provides a potential mechanistic framework for exploring these enhancements, individual responses to cannabis are highly variable. Furthermore, any attempt to optimize for CAP domains must rigorously consider potential risks, including cognitive impairment, dependence, adverse psychiatric effects, and the critical need for careful titration, appropriate chemovar selection, and thorough individual assessment. This section should be viewed as a forward-looking exploration of research questions rather than a guide for current application.

5.1. Creativity

Creativity involves divergent thinking, novel idea generation, and associative flexibility. ECAP allows us to hypothesize how the following elements might contribute to potential creative enhancement by modulating underlying neurocognitive processes:

- Dopamine (DA): Theoretically, modulation of reward salience and novelty-seeking via mesocortical activation (THC, limonene) (Section 4.1) could potentially lower thresholds for associative thinking. However, excessive or poorly timed DA activation can also impair focused creative work.
- Serotonin (5-HT1A): It is hypothesized that reduced anxiety barriers through CBD (Section 4.2) might possibly foster a more open and less inhibited mental state conducive to exploration. This requires careful balancing to avoid anxiolysis that could reduce motivation.

- CB1 Activation: Speculatively, moderate disruption of habitual patterns and stimulation of the Default Mode Network (DMN) (Kowal et al., 2015) could facilitate novel connections and divergent thinking. Conversely, excessive CB1 activation, particularly with THC, is known to impair cognitive functions vital for creativity.

- TRPV1 and α-pinene: Potential for sensory tuning via TRPV1 (Section 3.1) and acetylcholine retention via α-pinene (Section 4.4) might theoretically enhance focus on creative tasks and sharpen sensory input. The actual impact on creative output remains unproven.

Functional outcome (Hypothesized): ECAP-guided modulation is hypothesized to potentially support increased idea generation, insight, and pattern recognition. However, the relationship between cannabis and creativity is exceedingly complex, dose-dependent, and currently lacks robust scientific consensus. High doses or inappropriate chemovars are well-documented to impair cognitive functions necessary for structured creative output. Extensive, well-controlled research with specific formulations and objective creativity metrics is urgently needed to validate any of these theoretical outcomes and to understand the narrow conditions, if any, under which such effects might be safely achieved.

5.2. Action

Action requires motivation, focus, and goal pursuit. ECAP highlights pathways that might theoretically support these functions, while also acknowledging significant counteracting risks:

- DA and CB1 (low-dose THC): Potential for initiation of reward-seeking behavior and increased goal salience (Section 4.1). This must be weighed against the risk of THC inducing amotivation or dependence with chronic use.

- HPA Axis Regulation: Hypothesized stress-buffering via CBD (Section 4.7.2) could potentially maintain an optimal physiological state for sustained effort.

- Noradrenergic & GPR55: Theoretical support for vigilance (Noradrenergic, Section 4.1, indirectly) and metabolic drive (GPR55, Section 3.2) might contribute to energy for action.

Functional outcome (Hypothesized): Modulation of these ECAP targets might theoretically contribute to reduced procrastination, increased motivation for task initiation, drive, and sustained goal-directed activity. It is crucial to reiterate that chronic high-dose THC can lead to significant amotivational states (Section 4.8) and other adverse effects. Thus, any ECAP-informed approaches exploring action enhancement would need to prioritize extremely low-dose or balanced chemovars and be subjected to rigorous testing to prove efficacy and safety over placebo and to clearly define risk profiles.

5.3. Performance

Performance—social, physical, or cognitive—relies on a delicate balance across neurotransmitters and hormonal systems. ECAP identifies several pathways theoretically relevant to exploring the optimization of performance states, balanced against known impairments:

- GABA/Glutamate: Potential for fine-tuned focus and inhibition via CB1 and terpenes like linalool (Section 4.3), theoretically reducing mental "noise." However, disruption of E/I balance can also impair performance.
- Oxytocin (CBD): Hypothesized social bonding, confidence, empathy (Section 4.7.1), potentially enhancing performance in social or team contexts.
- Acetylcholine (α-pinene): Theoretical memory and attention optimization (Section 4.4), crucial for cognitive tasks. This needs to be balanced against THC's known ACh-impairing effects.
- Anti-Inflammatory Axis: CB2, PPARγ, and TRPV1 desensitization (Sections 2.2, 3.3, 3.1), theoretically supporting physiological readiness and reducing "sickness behavior" that can impair performance.

Functional outcome (Hypothesized): Targeted ECAP modulation is hypothesized to aim to foster emotional regulation, flow states, and optimized mental-physical integration. The optimal ECAP profile for performance, if one exists, is highly context-dependent (e.g., athlete vs. public speaker) and currently unsubstantiated by robust research. Over-reliance, improper use, or poorly chosen chemovars can, and often do, lead to significant performance decrements. Any claims of performance enhancement require extensive validation.

5.4. The CAP Engine

The following table (Table 3) summarizes hypothesized CAP domains, potential ECAP targets, example cannabis constituents, and theoretical functional outcomes. These relationships are highly speculative, often dose-dependent, subject to significant individual variability, and require rigorous scientific investigation before any practical application can be considered. (Russo, 2011; plus specific section citations as in the "ADDITION" document's table).

Table 3: The CAP Engine: How ECAP Powers High-Functioning States

Domain	Key ECAP Targets/Pathways Activated (Examples)	Example Cannabis Constituents	Potential Functional Outcome	Relevant Citations (for mechanism)
Creativity	Dopaminergic system; 5-HT1A receptors; CB1 (moderate activation); TRPV1 channels; AChE inhibition (terpenes)	THC, CBD, Limonene, α-Pinene, Myrcene	Idea generation, insight, divergent thinking	(Sec 4.1, 4.2, 2.1, 3.1, 4.4; Bloomfield et al., 2016; García-Gutiérrez et al., 2020; Kennedy et al., 2011)
Action	Dopaminergic system; HPA Axis regulation; CB1 (low-dose); GPR55; AChE inhibition (terpenes)	THC (low dose), CBD, α-Pinene, Limonene	Focused drive, task initiation, motivation	(Sec 4.1, 4.7.2, 2.1, 3.2, 4.4; Lupica et al., 2004; Zuardi et al., 2008; Perry et al., 2000)
Performance	GABA/Glutamate balance; HPA Axis regulation; Oxytocin system; ACh modulation; CB2/PPARγ/TRPV1 (anti-inflammatory)	THC (balanced), CBD, Linalool, α-Pinene, β-Caryophyllene	Confidence, stress resilience, flow, focus	(Sec 4.3, 4.7.2, 4.7.1, 4.4, 2.2, 3.3, 3.1; Wilson & Nicoll, 2002; Schiavon et al., 2020; Gertsch et al., 2008)

Caption: This table outlines key ECAP targets, example cannabis constituents, and potential functional outcomes related to Creativity, Action, and Performance. Interactions are complex and influenced by dose, chemovar profile, and individual biology. Citations refer to sections where mechanisms are more fully described or directly relevant.

Additional Notes:

- **Creativity Domain**: ECAP modulation can enhance associative thinking through moderate CB1 activation (THC) in prefrontal cortex and striatum, balanced by 5-HT1A agonism (CBD) for anxiety reduction. Terpenes like α-pinene may counteract short-term memory impairment through AChE inhibition, potentially preserving idea development.
- **Action Domain**: Low-dose CB1 activation can stimulate dopamine release in motivation circuits, while CBD's regulation of the HPA axis may reduce performance anxiety that inhibits action. Terpenes like limonene may enhance mood and drive through dopaminergic and serotonergic modulation.
- **Performance Domain**: GABA/glutamate balance optimization through balanced CB1 modulation can enhance "flow state" access, while anti-inflammatory effects via CB2/PPARγ/TRPV1 (β-caryophyllene, CBD) may improve recovery and reduce fatigue. Oxytocin system modulation may enhance social performance and team coordination.

Table 3: The CAP Engine: How ECAP Powers High-Functioning States

Caption: This table outlines potential ECAP targets, example cannabis constituents, and hypothesized functional outcomes related to Creativity, Action, and Performance. Interactions are complex, speculative, and influenced by dose, chemovar profile, and individual biology. This table is for conceptual and research guidance only; it is not a prescription for use. Citations refer to sections where mechanisms are more fully described or directly relevant.

https://claude.ai/public/artifacts/9ef0b940-06df-4e8b-ae59-14056f5d0eeb

5.5. Integrating ECAP for Intentional Modulation

Understanding ECAP could theoretically allow for a shift from haphazard cannabis use to a more intentional, research-driven approach aimed at investigating specific CAP outcomes. This would necessarily involve:

- Chemovar Selection: Hypothetically matching constituent profiles to intended CAP outcomes, based on preclinical data and early-phase clinical trials.
- Titration: Strict adherence to low/moderate doses to avoid cognitive impairment and other potential adverse effects, with safety as the primary concern.
- Set and Setting: Recognizing that psychological and environmental context modulate effects.
- Personalization: Considering genetics, baseline neurochemistry, individual sensitivities, prior exposure, and contraindications.
- Comprehensive Risk Profile Consideration: Thoroughly assessing individual susceptibility to potential adverse cognitive, affective, physiological, and psychiatric effects based on these personalized factors, including potential for dependence or interaction with other medications or conditions.

ECAP reframes cannabis as a modular tool for potential neurocognitive tuning, creating pathways for exploring precision wellness and human potential, always guided by scientific evidence, ethical considerations, and a primary focus on safety and harm reduction.

Practical Use Cases

To illustrate the potential applied value of the ECAP framework, the following use cases demonstrate how cannabinoid formulations could theoretically be strategically selected or developed for targeted outcomes based on ECAP mapping. These

examples span clinical, performance (where applicable and with significant caveats regarding current evidence), and wellness domains. They aim to emphasize how ECAP can guide research towards maximizing efficacy while rigorously considering individual variability, potential adverse effects, and the paramount importance of safety and evidence-based practice. These are illustrative examples of how ECAP might inform future therapeutic development, not current treatment guidelines.

6.1. Chronic Pain and Inflammation Management

ECAP Targets: CB2, TRPV1, PPARγ, glycine receptors

Key Constituents (Example): CBD, β-caryophyllene, CBG, myrcene

Proposed Mechanisms: Immune suppression, neuroinflammation reduction, nociceptive desensitization.

Potential Outcome: Improved daily function, reduced pharmaceutical reliance, potentially with an improved side-effect profile compared to conventional analgesics. This requires careful patient selection, dose titration to manage potential side effects (e.g., sedation from myrcene, GI effects from high-dose CBD), and consideration of interactions with existing medications.

6.2. Anxiety and Mood Dysregulation

ECAP Targets: 5-HT1A, CB1 (low-dose), oxytocin system, HPA axis

Key Constituents (Example): CBD, linalool, limonene, THC (low-dose)

Proposed Mechanisms: Anxiolysis via serotonin signaling, stress modulation, and gentle CB1 engagement.

Potential Outcome: Calmer baseline, increased resilience to daily stressors. This is hypothesized to be achieved through targeted modulation aimed at minimizing anxiogenic risks associated with less specific cannabinoid exposure, particularly THC-dominant chemovars. Vigilance for paradoxical anxiety or mood changes, especially with THC, is essential, and individual responses must be closely monitored.

6.3. Sleep Optimization

ECAP Targets: GABA, 5-HT, melatonin axis, TRPV1

Key Constituents (Example): CBN, linalool, myrcene, CBD

Proposed Mechanisms: Enhanced inhibitory neurotransmission, circadian support, and anxiolysis.

Potential Outcome: Faster sleep onset, deeper sleep architecture, fewer awakenings. The focus is on formulations that avoid next-day cognitive impairment or grogginess. However, long-term effects on sleep architecture and potential for dependence or tolerance require further research and careful consideration. Individual sensitivity to sedative effects must be managed.

6.4. Focus and Cognitive Clarity

ECAP Targets: Acetylcholine, dopamine, glutamate

Key Constituents (Example): α-pinene, limonene, CBD, THCV

Proposed Mechanisms: Cholinesterase inhibition, balanced excitation, prefrontal cortex stimulation.

Potential Outcome (Hypothesized): Enhanced working memory, reduced distractibility. This would theoretically be achieved by selecting constituents that support cognitive function while actively mitigating potential THC-induced impairments or other adverse cognitive effects. This area is highly speculative and requires substantial research to validate any claims and to ensure that net cognitive benefits outweigh potential detriments. Risk of cognitive impairment from poorly formulated or dosed products is significant.

6.5. Neurocognitive Recovery and Brain Health

ECAP Targets: PPARγ, CB2, glutamate/GABA balance, oxytocin

Key Constituents (Example): CBD, CBG, β-caryophyllene, apigenin-rich terpenes

Proposed Mechanisms: Neuroinflammation reduction, neurogenesis support, synaptic stabilization, oxidative stress reduction.

Potential Outcome: Support for post-injury recovery, neuroprotection, and mitigation of age-related cognitive decline.

The ECAP framework provides a mechanistic explanation for how cannabinoids may support brain healing and resilience, especially after injury or in age-related decline. Cannabinoids such as CBD and CBG influence PPARγ and CB2 signaling, which play key roles in reducing oxidative stress and modulating inflammatory responses (Ibeas Bih et al., 2015; Pertwee, 2008).

Neuroplasticity and synaptic repair are further hypothesized to be supported through ECAP-aligned modulation of glutamate/GABA balance and oxytocin pathways. These effects position ECAP-guided cannabis formulations as potential adjuncts in neurorehabilitation and cognitive longevity strategies. The aim is for interventions that are both effective and well-tolerated, which necessitates careful formulation,

personalized dosing, and a thorough understanding of individual patient profiles and potential drug interactions.

Table 4: Selected Terpenes: Properties and ECAP Interactions

Terpene	Aroma	ECAP Targets	Effects	References
Limonene	Citrus	5-HT, DA, Adenosine A2A	Anxiolytic, antidepressant	Komori et al., 1995; Lima et al., 2013
α-Pinene	Pine	AChE, GABA, CB2	Memory enhancement, anti-inflammatory	Kennedy et al., 2011; Kim et al., 2015
Linalool	Floral	GABA-A, 5-HT, Adenosine A2A	Sedative, anxiolytic, anticonvulsant	Linck et al., 2010; Hosseini et al., 2022
Myrcene	Earthy	TRPV1, Prostaglandins	Sedative, analgesic, ↑ BBB permeability	Russo, 2011; Jansen et al., 2019
β-Caryophyllene	Spicy	**CB2**, PPARs	Anti-inflammatory, analgesic, anxiolytic	Gertsch et al., 2008; Klauke et al., 2014
Humulene	Woody	Unknown (anti-inflammatory)	Anti-inflammatory, anorectic	Rogerio et al., 2009

Abbreviations: 5-HT = Serotonin; DA = Dopamine; AChE = Acetylcholinesterase; GABA = Gamma-aminobutyric acid; TRPV1 = Transient receptor potential vanilloid 1; PPARs = Peroxisome proliferator-activated receptors; BBB = Blood-brain barrier

Caption: Terpenes contribute to the entourage effect by targeting diverse ECAP nodes, enhancing or modulating cannabinoid effects (Russo, 2011; Nuutinen, 2018).

Table 4: Selected Terpenes: Properties and ECAP Interactions

Caption: Terpenes contribute to the entourage effect by targeting diverse ECAP nodes, enhancing or modulating cannabinoid effects. Their inclusion in formulations must be considered for both their potential synergistic benefits and their own pharmacological activities, including potential for sensitization or other adverse reactions (Russo, 2011; Nuutinen, 2018). Abbreviations: 5-HT = Serotonin; DA = Dopamine; AChE = Acetylcholinesterase; GABA = Gamma-aminobutyric acid; TRPV1 = Transient receptor potential vanilloid 1; PPARs = Peroxisome proliferator-activated receptors; BBB = Blood-brain barrier.
https://claude.ai/public/artifacts/cc98d2ed-719e-4eb7-826b-42ce466364e3

Clinical and Therapeutic Applications: An ECAP-Guided Approach

The ECAP model aims to enable more precise and predictive approaches in the development and application of clinical cannabis therapy. By recognizing the full spectrum of endocannabinoid-associated targets, it is hypothesized that clinicians and researchers can work towards optimizing formulations based on patient-specific symptomology, neurobiology, and individual risk-benefit profiles. The applications discussed below represent areas where ECAP-guided research could lead to improved therapeutic strategies, contingent upon rigorous clinical validation and a strong emphasis on patient safety.

7.1. Mental Health Interventions

Conditions (Examples): Generalized Anxiety Disorder, PTSD, Depression

Key ECAP Targets (for investigation): 5-HT1A, HPA axis, GABAergic tone, CB1 modulation (low-level)

Formulation Strategies (for research): High-CBD, low-THC profiles with calming terpenes (e.g., linalool, myrcene), selected to theoretically maximize anxiolytic effects while minimizing potential for THC-induced anxiety, cognitive side effects, or other adverse psychiatric events.

Potential Outcome (Target for research): Reduced anxiety, improved sleep, mood stabilization. Achieving these outcomes requires careful patient screening, precise dosing, monitoring for individual responses (including paradoxical effects), and consideration of polypharmacy interactions.

7.2. Chronic Pain and Neuropathic Disorders

Conditions (Examples): Fibromyalgia, neuropathy, multiple sclerosis

Key ECAP Targets (for investigation): CB2, TRPV1, glycine receptors, PPARγ

Formulation Strategies (for research): Combinations such as CBD + β-caryophyllene + CBG with desensitizing TRPV1 activity, aiming for multi-target analgesia with a potentially reduced risk of central nervous system side effects associated with high-dose THC or opioids.

Potential Outcome (Target for research): Decreased pain perception, improved physical function. Managing expectations, titrating to effect while monitoring for side effects (e.g., GI issues, sedation), and understanding long-term efficacy and safety are critical.

7.3. Neurodegenerative Diseases

Conditions (Examples): Alzheimer's, Parkinson’s, Huntington’s

Key ECAP Targets (for investigation): CB2, PPARγ, glutamatergic modulation, oxidative stress reduction

Formulation Strategies (for research): CBD-rich formulations with antioxidants and neuroprotective terpenes, designed to offer potential neuroprotective support with good tolerability in vulnerable patient populations.

Potential Outcome (Target for research): Slowed progression, neuroprotection, improved quality of life.

Cannabinoid-based therapies are being investigated for potential disease-modifying effects in neurodegenerative disorders by targeting oxidative damage, neuroinflammation, and disrupted glutamate signaling (Zou & Kumar, 2018; Bolognini et al., 2010). Within ECAP, CB2 and PPARγ receptors are conceptualized as central modulators in mitigating microglial overactivation and enhancing mitochondrial function (Ibeas Bih et al., 2015). CBD-rich formulations complemented by antioxidant terpenes (e.g., pinene, linalool) are hypothesized to help sustain neurocognitive integrity across progressive conditions. This is a complex area requiring extensive long-term studies to establish efficacy and safety.

7.4. Pediatric Epilepsy and Seizure Disorders

Condition (Examples): Dravet Syndrome, Lennox-Gastaut Syndrome

Key ECAP Targets (Established & for further investigation): GABA/glutamate balance, TRPV1, 5-HT modulation

Formulations (Established & for refinement): Purified CBD isolate or broad-spectrum formulations (e.g., Epidiolex), with precise dosing critical for efficacy and safety in pediatric populations. ECAP may inform the development of next-generation formulations with enhanced efficacy or reduced side effect profiles by considering minor cannabinoids and terpenes.

Outcome (Established & Target for improvement): Seizure frequency reduction, developmental support. Close medical supervision and careful management of drug interactions and side effects remain paramount.

7.5. Oncology Supportive Care

Conditions (Examples): Chemotherapy-induced nausea, pain, appetite loss

Key ECAP Targets (for investigation): 5-HT3A, CB1, appetite pathways

Formulation Strategies (for research): Balanced THC/CBD with terpenes like limonene and β-myrcene, titrated carefully to manage symptoms effectively while

minimizing psychoactive burden and other THC-related adverse effects (e.g., anxiety, cognitive impairment).

Potential Outcome (Target for research): Improved appetite, reduced nausea and fatigue, mood enhancement. A thorough risk-benefit analysis is essential for each patient, considering their overall condition and treatment regimen.

ECAP endeavors to provide a roadmap for integrating cannabinoid therapeutics into evidence-based care—supporting clinicians and researchers in the investigation of matching the right combination of molecules to the right patient at the right time, optimizing for both therapeutic benefit and patient safety.

(The Gut-Brain-Immune Axis plays a significant role in many systemic conditions, including those with inflammatory or neuroinflammatory components discussed above. Figure 4 illustrates key interactions within this axis as conceptualized by ECAP).

Figure 4: Gut-Brain-Immune Axis Interactions



Figure 4: Gut-Brain-Immune Axis Interactions

Caption: Cannabinoids modulate the gut-brain-immune axis by potentially enhancing gut barrier function, reducing systemic and neuroinflammation, and influencing mood and cognition. The bidirectional communication between these systems demonstrates how gut-level interactions can influence central nervous

system function (Cani et al., 2016; Stella, 2010). ECAP provides a framework for exploring these complex interactions for therapeutic benefit.
https://www.canva.com/design/DAGoEwt0ICk/N9X049sQDRJg18cI0CwJww/view?utm_content=DAGoEwt0ICk&utm_campaign=designshare&utm_medium=link2&utm_source=uniquelinks&utlId=hd8b54737b2

Commercial and Research Innovations

The ECAP framework not only aims to inform clinical and wellness strategies but also presents opportunities for responsible commercialization and rigorous scientific advancement. By proposing a new way to conceptualize how cannabis products are developed, evaluated, and delivered, ECAP has the potential to drive innovation across multiple sectors, always prioritizing evidence-based approaches and ethical considerations.

8.1. Product Development and Chemovar Engineering

Opportunity: To explore the design of products with specific ECAP profiles hypothesized to be beneficial for mood, focus, pain, or performance.

Potential Application: Use terpene and cannabinoid mapping to guide research into engineering consistent, purpose-built formulations, grounded in ECAP's mechanistic understanding and validated through preclinical and clinical trials.

Potential Impact: Could move the industry beyond anecdotal strain names towards validated, outcome-driven SKUs, potentially enhancing consumer trust and therapeutic predictability, if supported by robust scientific evidence and transparent communication.

8.2. Personalized Therapeutics and Smart Formulations

Opportunity: To investigate the integration of ECAP principles into AI-driven personalization engines for research and, eventually, potential clinical application.

Potential Application: To develop systems that could match user genetics, biomarkers, ECAP-informed neurobiology profiles, and lifestyle to theoretically ideal cannabinoid-terpene combinations, subject to extensive validation and ethical oversight.

Potential Impact: Could offer a pathway towards precision wellness and scalable cannabinoid-based health platforms, though requiring significant data integration, robust validation through controlled trials, stringent data privacy measures, and clear regulatory frameworks.

Figure 5: ECAP Smart Personalization Engine Example



Figure 5: ECAP Smart Personalization Engine Example

Caption: Conceptual illustration of a potential AI-driven platform integrating ECAP principles, user-specific data (genetics, biomarkers, lifestyle), and comprehensive chemovar profiles to hypothetically generate personalized cannabinoid-terpene recommendations for targeted outcomes. This figure represents a long-term research goal requiring substantial development and validation.

https://www.canva.com/design/DAGoJFAWMao/zI10o9gNU8FI8UL5WuF8Iw/view?utm_content=DAGoJFAWMao&utm_campaign=designshare&utm_medium=link2&utm_source=uniquelinks&utlId=h012b4adbbb

This figure demonstrates how the ECAP framework could theoretically be operationalized into a practical AI-driven personalization engine that would aim to:

(The sub-points under Input Integration, AI Processing, Personalized Outputs, and Continuous Optimization are largely okay as they describe the hypothetical function, but the introductory phrasing sets the right cautious tone).

- Personalized Outputs:
    - Clinical Applications: Targeted interventions for investigation in chronic pain, anxiety, and sleep disorders.

    - CAP Enhancement: Hypothetical optimization for exploration in creativity, action, and performance domains, with extreme caution and a focus on safety and empirical validation.
    - Wellness Optimization: Potential support for stress resilience, neuroprotection, and immune modulation.
- Continuous Optimization:
    - Real-time feedback loop would enable continuous learning and refinement based on user responses and outcomes, representing a future vision for evolving from generic cannabis use to precision neurocognitive modulation as outlined in the theoretical ECAP framework, always under strict ethical and scientific guidelines.

8.3. Digital Health and Monitoring Platforms

Opportunity: To explore combining ECAP-based formulations with biofeedback tools in research settings and for potential future therapeutic monitoring.

Potential Application: Track mood, cognition, sleep, and inflammation markers via wearables to assess ECAP target engagement and outcomes, initially for data collection in clinical trials and later, if validated, for personalized therapy adjustment.

Potential Impact: Closed-loop systems for real-time optimization of cannabinoid therapy, could potentially improve adherence and individualized dosing strategies, enhancing both efficacy and safety if rigorously tested and implemented.

8.4. Research and Translational Science

Opportunity: Position ECAP as a testable, multidisciplinary research framework to advance fundamental understanding and evidence-based applications.

Application: Collaborate with academic institutions to study ECAP across neuropsychiatric, metabolic, and neurodevelopmental domains, utilizing standardized ECAP-aligned chemovars and validated outcome measures.

Impact: Aims to bridge pharmacology, systems neuroscience, and clinical research, facilitating the translation of basic science discoveries into validated clinical practice and responsible product development.

8.5. Licensing, Education, and Certification Pathways

Opportunity: Develop ECAP-informed practitioner training and certification programs grounded in scientific evidence and ethical practice.

Potential Application: License ECAP IP to healthcare systems, academic programs, or product manufacturers to encourage and ensure scientifically sound application of the model as it evolves and is validated.

Potential Impact: Could help establish a standard of excellence and deepen scientific credibility (American Psychological Association, 2020), fostering responsible innovation in the cannabis space, driven by evidence rather than marketing claims.

By providing a mechanistic foundation and a predictive model that is open to refinement and validation, ECAP aims to help shape the future of cannabinoid wellness—from dispensary shelves to clinical trials, from biohackers to biotech—always prioritizing patient/consumer safety and scientifically robust outcomes.

Research Gaps and Strategic Priorities

The ECAP framework sets the stage for a new era of cannabis research, but key gaps must be addressed to refine, validate, and responsibly scale this model. Addressing these priorities is essential to unlock ECAP's full potential for both well-substantiated therapeutic application and the careful exploration of neurocognitive optimization, always prioritizing safety and efficacy.

9.1. Human Clinical Trials with ECAP-Mapped Formulations

Gap: Most cannabis trials use poorly characterized products or single-molecule isolates, limiting translational relevance for real-world full-spectrum cannabis use and the complex interactions ECAP describes.

Need: Rigorous, placebo-controlled Randomized Controlled Trials (RCTs) utilizing full-spectrum, analytically verified, ECAP-aligned chemovars. These trials should incorporate robust phenotype tracking, objective biomarkers (see Section 9.4), and measures relevant to both therapeutic outcomes and the hypothesized CAP domains (see Section 5), with clearly defined primary endpoints and safety monitoring.

9.2. Mapping the Interactions of Minor Cannabinoids and Terpenes

Gap: Limited pharmacological data on the individual and interactive effects of numerous minor cannabinoids (e.g., CBC, THCV, CBG, CBN) and less abundant terpenes, which are integral to ECAP's comprehensive model.

Need: Systematic preclinical and clinical evaluation of these constituents’ ADME (absorption, distribution, metabolism, excretion) profiles, specific molecular targets within ECAP, dose-response relationships, and their synergistic or modulatory roles in ECAP pathway engagement. This includes investigating specific

terpene-cannabinoid ratios hypothesized by ECAP to produce distinct neurocognitive effects, both beneficial and adverse.

9.3. Longitudinal Effects on Neurocognitive Architecture

Gap: Insufficient understanding of the long-term impact of consistent, daily cannabis use (particularly with varying chemovar profiles as conceptualized by ECAP) on both therapeutic outcomes and potentially CAP-related neurocognitive networks and overall brain health, especially during critical neurodevelopmental periods.

Need: Prospective, longitudinal neuroimaging (e.g., fMRI, PET) and behavioral studies tracking chronic modulation effects of defined ECAP-aligned chemovars on brain structure, function, connectivity, and performance across relevant domains. Such studies must also assess the potential for sustained neuroplastic changes, both adaptive and maladaptive, to provide a balanced view of long-term use.

9.4. Biomarker Development and ECAP-Based Diagnostics

Gap: Absence of validated, accessible diagnostic tools to objectively assess an individual's baseline ECAP network state or to reliably match users with optimal formulations for desired outcomes while minimizing risk.

Need: Identification and validation of a panel of genetic (e.g., CNR1, FAAH, COMT, CYP2C9 polymorphisms), epigenetic, microbiome, and neurochemical (e.g., endocannabinoid tone, inflammatory markers, neurotransmitter metabolites) biomarkers. These biomarkers are essential to guide personalization, predict response variability (including adverse effect susceptibility), and objectively measure ECAP target engagement in research and, eventually, clinical settings.

9.5. Ethical and Regulatory Infrastructure

Gap: Significant misalignment between the rapidly emerging science of cannabis, particularly complex models like ECAP, and often outdated or overly simplistic regulatory policies and public understanding, which can hinder responsible research and safe access.

Need: ECAP-aligned advocacy, multi-stakeholder education (for policymakers, healthcare providers, and the public) to modernize regulatory frameworks, facilitate responsible research, and support appropriate clinical integration (Russo, 2011; Ibeas Bih et al., 2015). This includes developing guidelines for responsible communication of ECAP-based claims, clearly distinguishing between established evidence and hypotheses, and ensuring equitable access to informed cannabis care.

These research priorities underscore the urgent need for multidisciplinary collaboration between neuroscientists, pharmacologists, clinicians, data scientists, and policy leaders to realize the validated and responsibly applied potential of the

ECAP model. A foundational first step would be to prioritize well-designed RCTs (9.1) and systematic characterization of minor constituents (9.2) to build the evidence base upon which other ECAP applications can be explored.

Theoretical and Translational Significance

The ECAP model stands at the intersection of theory and potential application, offering a new systems-level lens to understand the broad spectrum of cannabis effects. Its significance lies not only in its proposed explanatory power but also in its potential translational utility—bridging bench science, clinical application, wellness design, and policy evolution (Zou & Kumar, 2018; Devinsky et al., 2017), contingent upon ongoing research and validation.

10.1. A Paradigm Shift in Cannabinoid Science

ECAP moves beyond reductionist models to embrace dynamic, multi-receptor, multi-system interactions.

It proposes to position cannabis not merely as a recreational or symptomatic tool but as a potential precision neurocognitive modulator, when its complex actions are fully understood and can be reliably guided.

10.2. Unifying Mechanisms Across Disciplines

By integrating neuroscience, pharmacology, psychology, and immunology, ECAP aims to unite fragmented domains of cannabis science.

This unified model is intended to foster collaboration across research, healthcare, wellness, and regulatory sectors.

10.3. Translational Relevance to Personalized Medicine

ECAP supports the shift from generalized cannabinoid use to investigating targeted, individualized strategies.

It aligns with the precision health movement and the development of emerging bioinformatics tools for personalized care, offering a theoretical framework for such advancements.

10.4. Empowering Innovation and Education

ECAP creates a framework for guiding the development of next-generation products, clinical protocols, and educational content, all of which require grounding in robust scientific evidence.

It encourages critical thinking and scientific rigor in the rapidly expanding cannabis industry, advocating for evidence over anecdote.

10.5. A Platform for the Future of Neuroscience-Driven Wellness

ECAP opens avenues to explore a new domain where neuroplasticity, emotional regulation, immune modulation, and peak performance might theoretically converge.

It aims to elevate the conversation around cannabis from anecdote to architecture—from culture to cognition, based on testable scientific principles.

By providing both a foundation and a forward path, ECAP endeavors to help redefine what cannabis can mean for medicine, performance, and human potential, if its hypotheses are validated and its applications are pursued responsibly.

Conclusion

The ECAP framework represents a bold conceptual step forward in cannabinoid science, offering a unified theory that attempts to account for the diverse and complex ways cannabis interacts with the human body and mind. By transcending the limitations of the traditional ECS model, ECAP integrates neurochemical, immunological, hormonal, and cognitive pathways into a systems-based architecture. This provides a foundation for profound research implications for understanding both the therapeutic potential and the intricate response profiles associated with cannabis, including the critical aspect of adverse effects and individual variability.

This white paper has:

- Introduced the conceptual architecture of ECAP and its core components.
- Mapped the proposed interactions between cannabinoids, neurotransmitters, and non-canonical targets.
- Presented the CAP model as a visionary, yet explicitly hypothetical, framework for future research into ECAP's application for neurocognitive optimization.
- Demonstrated potential real-world use cases across medical, wellness, and performance contexts, emphasizing the need for validation and cautious application.
- Identified commercial, research, and translational opportunities for innovation, stressing an evidence-first and ethical approach.

As cannabis science continues to evolve, the ECAP model positions Dr. Jeff Bullock and his collaborators at the forefront of a paradigm shift—one that sees cannabis not as a one-size-fits-all remedy, but as a potential precision instrument for healing, performance, and human potential, when understood through comprehensive, systems-level insight and applied responsibly based on validated evidence.

ECAP is not just a framework—it is an invitation: to rethink, to personalize based on evidence, to innovate responsibly, and to lead with scientific integrity.

About the Author

Dr. Jeff Bullock, PharmD is a distinguished neuropharmacologist, innovative educator, and the visionary founder of PRISM AI Consultants. His career is a testament to his ability to operate at the confluence of deep scientific understanding, strategic leadership, and cutting-edge technological application. With a foundational background in pharmacy and years of impactful leadership within major healthcare organizations like CVS Health, Dr. Bullock cultivated a profound understanding of systems neuroscience in practice, observing firsthand the complex interplay of pharmacology, patient neurobiology, and treatment outcomes.

At CVS Health, Dr. Bullock's trajectory from Pharmacy Supervisor to District Leader saw him spearheading initiatives that significantly enhanced patient care, operational efficiency, and healthcare outcomes across large districts. He led teams of up to 25 pharmacy managers, eliminated critical operational challenges in multiple stores, and served as a Divisional Immunization Captain and Patient Care Divisional Expert, demonstrating a consistent ability to exceed performance expectations and drive positive change. His commitment to public health was further evidenced by conducting over 100 opioid prevention presentations, showcasing his dedication to education and community well-being.

This extensive experience in navigating and optimizing complex healthcare systems, combined with his pharmaceutical expertise, laid the groundwork for his subsequent ventures. Transitioning into entrepreneurship, first with CJ Freight and Logistics where he honed his operational and business management acumen, Dr. Bullock then launched PRISM AI Consultants. Here, he has rapidly established himself as a thought leader in digital health innovation and the ethical application of generative AI. At PRISM, he has led strategic direction in AI, developed and executed tailored consulting services impacting hundreds of clients across diverse industries, and advised prestigious bodies like the United Nations on AI policy, emphasizing responsible and ethical deployment. His pioneering approaches to AI education, focusing on real-world applications of tools like GPT-4, empower clients and contribute to a broader understanding of AI's transformative potential.

It is from this unique synthesis of experience—a deep understanding of pharmacology and systems neuroscience gained through years in demanding healthcare leadership roles, coupled with his current immersion in AI strategy, ethical AI development, and bridging complex scientific models with potential practical applications—that Dr. Jeff Bullock developed the ECAP (Endocannabinoid-Associated Pathways) framework. He recognized the limitations of existing models in fully explaining the nuanced effects of cannabis and sought to create a more comprehensive, systems-level understanding. The ECAP framework is thus designed to expand the possibilities of cannabinoid science, moving beyond traditional paradigms to provide a robust foundation for evidence-based inquiry and

the development of future precision neurocognitive interventions in wellness, medicine, and human performance. Dr. Bullock's vision for ECAP is not just as a theoretical model, but as a dynamic tool to guide responsible research, foster innovation, and ultimately, enhance human health and potential.

Glossary

2-AG – 2-Arachidonoylglycerol
ACh – Acetylcholine
AChE – Acetylcholinesterase
AEA – Anandamide (N-arachidonoylethanolamine)
CAP – Creativity, Action, and Performance
CB1/CB2 – Cannabinoid receptor types 1 and 2
CBD – Cannabidiol
CBG – Cannabigerol
Chemovar – A cannabis variety classified by its distinct chemical profile
DA – Dopamine
DMN – Default Mode Network
ECAP – Endocannabinoid-Associated Pathways
ECS – Endocannabinoid System
Entourage Effect – Synergistic interaction of cannabis compounds
FAAH – Fatty acid amide hydrolase
GABA – Gamma-aminobutyric acid
GLU – Glutamate
GPCRs – G protein-coupled receptors
GPR55 – G protein-coupled receptor 55
HPA Axis – Hypothalamic-Pituitary-Adrenal Axis
Phytocannabinoids – Cannabinoids produced by the Cannabis sativa plant
PPARγ – Peroxisome Proliferator-Activated Receptor Gamma
Terpenes – Aromatic compounds in cannabis contributing to effects and aroma
THC – Tetrahydrocannabinol
TRPV1 – Transient Receptor Potential Vanilloid Type 1

Table of Figures and Tables

References

AbBound, S., & Abul-Husn, N. S. (2019). Artificial intelligence in drug development: a new frontier. Clinical Pharmacology & Therapeutics, 106(1), 35–37.

Ahrens, J., Demir, R., Leuwer, M., de la Roche, J., Krampfl, K., Foadi, N., ... & Ghadban, C. (2009). The nonpsychotropic cannabinoid cannabidiol modulates and directly activates alpha-1 and alpha-1-beta glycine receptor function. Pharmacology, 83(4), 217–222.

Al-Sayed, R. K. R., Imbrici, P., D'Adamo, M. C., & Nicolotti, O. (2016). The orphan G protein-coupled receptor GPR55: A new potential therapeutic target in epilepsy. Epilepsy Research, 126, 94–102.

Alhamorila, F. Q., Lostia, A. M., O'Sullivan, S. E., & O'Driscoll, C. M. (2011). Cannabinoids mediate opposing effects on inflammation-induced intestinal permeability. British Journal of Pharmacology, 162(5), 1197–1212.

American Psychiatric Association. (2013). Diagnostic and statistical manual of mental disorders (5th ed.). Arlington, VA: American Psychiatric Publishing.

American Psychological Association. (2020). Publication manual of the American Psychological Association (7th ed.). APA.

Ashton, C. H., Moore, P. B., Gallagher, P., & Young, A. H. (2005). Cannabinoids in bipolar affective disorder: a review and discussion. Journal of Psychopharmacology, 19(3), 293–300.

Bambico, F. R., Katz, N., & Gobbi, G. (2007). Cannabinoids and the serotonin system: a clinical and therapeutic perspective. In L. F. G., & R. S. T. (Eds.), Cannabinoids and the Brain (pp. 261–290). Birkhäuser Basel.

Barann, M., Molderings, G., Brüss, M., Bönisch, H., Urban, B. W., & Göthert, M. (2002). Direct inhibition by cannabinoids of human 5-HT3A receptors: a possible

involvement of an allosteric modulatory site. British Journal of Pharmacology, 137(5), 589–596.

Barnes, M. P. (2006). Sativex®: clinical efficacy and tolerability in the treatment of symptoms of multiple sclerosis and neuropathic pain. Expert Opinion on Pharmacotherapy, 7(5), 607–615.

Barnes, N. M., & Sharp, T. (1999). A review of central 5-HT receptors and their function. Neuropharmacology, 38(8), 1083–1152.

Ben-Shabat, S., Fride, E., Sheskin, T., Tamiri, T., Rhee, M. H., Vogel, Z., ... & Mechoulam, R. (1998). An entourage effect: inactive endogenous fatty acid glycerol esters enhance 2-arachidonoyl-glycerol cannabinoid activity. European Journal of Pharmacology, 353(1), 23–31.

Benito, C., Nuñez, E., Tolon, R. M., Carrier, E. J., Rábano, A., Hillard, C. J., & Romero, J. (2003). Cannabinoid CB2 receptors are expressed in human brain microglial cells. Journal of Neuroscience, 23(35), 11136–11141.

Bento, A. F., Marcon, R., Dutra, R. C., Claudino, R. F., Cola, M., Leite, D. F., & Calixto, J. B. (2011). β-Caryophyllene inhibits dextran sulfate sodium-induced colitis in mice through CB2 receptor activation and PPARγ pathway. The American Journal of Pathology, 178(3), 1153–1166.

Bergamaschi, M. M., Queiroz, R. H., Chagas, M. H. N., de Oliveira, D. C. G., De Martinis, B. S., Kapczinski, F., ... & Crippa, J. A. S. (2011). Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naive social phobia patients. Neuropsychopharmacology, 36(6), 1219–1226.

Berrendero, F., & Maldonado, R. (2002). Involvement of the opioid system in the anxiolytic-like effects of cannabinoids. Psychopharmacology, 163(1), 111–117.

Bhattacharyya, S., Fusar-Poli, P., Borgwardt, S., Martin-Santos, R., Nosarti, C., O'Carroll, C., ... & McGuire, P. (2009). Modulation of memory and other cognitive functions by Δ9-tetrahydrocannabinol in subjects with a previous psychotic episode. Archives of General Psychiatry, 66(12), 1308–1317.

Bisogno, T., Hanus, L., De Petrocellis, L., Tchilibon, S., Ponde, D. E., Brandi, I., ... & Di Marzo, V. (2001). Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. British Journal of Pharmacology, 134(4), 845–852.

Black, D. S., & Slavich, G. M. (2016). Mindfulness meditation and the immune system: a systematic review of randomized controlled trials. Annals of the New York Academy of Sciences, 1373(1), 13–24.

Bloomfield, M. A. P., Ashok, A. H., Volkow, N. D., & Howes, O. D. (2016). The effects of Δ9-tetrahydrocannabinol on the dopamine system. Nature, 539(7629), 369–377.

Bloomfield, M. A. P., Green, S. F., Hindocha, C., Yamamori, Y., Yim, J. L. L., Jones, A. P. M., ... & Howes, O. D. (2019). The effects of acute cannabidiol on anhedonia and amotivation in men with low anhedonia. Journal of Psychopharmacology, 33(8), 977–987.

Bolognini, D., Costa, B., Maione, S., Comelli, F., Marini, P., Di Marzo, V., & Parolaro, D. (2010). The plant cannabinoid Δ^9-tetrahydrocannabivarin can decrease signs of cannabinoid withdrawal in rats. British Journal of Pharmacology, 160(3), 633–645.

Bossong, M. G., van Berckel, B. N. M., Boellaard, R., Zuurman, L., Schuit, R. C., Kuin, A., ... & Jager, G. (2014). Δ9-Tetrahydrocannabinol induces dopamine release in the human striatum. Neuropsychopharmacology, 39(7), 1713–1721.

Bouaboula, M., Perrachon, S., Milligan, L., Canat, X., Rinaldi-Carmona, M., Portier, M., ... & Casellas, P. (1997). A selective inverse agonist for central cannabinoid receptor inhibits mitogen-activated protein kinase activation stimulated by anandamide. Journal of Biological Chemistry, 272(35), 22330–22339.

Breivogel, C. S., Childers, S. R., Deadwyler, S. A., Hampson, R. E., Vogt, L. J., & Sim-Selley, L. J. (1999). Chronic Δ9-tetrahydrocannabinol treatment produces a time-dependent tolerance to its psychological and physiological effects in rats. Journal of Pharmacology and Experimental Therapeutics, 288(2), 549–558.

Brown, A. J. (2007). Novel cannabinoid receptors. British Journal of Pharmacology, 152(5), 567–575.

Brown, T. T., & Dobs, A. S. (2002). Endocrine effects of marijuana. Journal of Clinical Pharmacology, 42(S1), 90S–96S.

Bruni, N., Della Pepa, C., Oliviero, M., Giglio, E., & Miele, E. (2018). Cannabinoid delivery systems for pain and inflammation treatment. Molecules, 23(10), 2478.

Buchbauer, G., Jirovetz, L., Jäger, W., Dietrich, H., & Plank, C. (1993). Aromatherapy: evidence for sedative effects of the essential oil of lavender after inhalation. Zeitschrift für Naturforschung C, 48(11-12), 856–859.

Buckley, N. E., McCoy, K. L., Mezey, E., Bonner, T., Zimmer, A., Felder, C. C., ... & Herkenham, M. (2000). Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB(2) receptor. European Journal of Pharmacology, 396(2-3), 141–149.

Budney, A. J., Hughes, J. R., Moore, B. A., & Vandrey, R. (2004). Review of the validity and significance of cannabis withdrawal syndrome. American Journal of Psychiatry, 161(11), 1967–1977.

Butterweck, V. (2003). Mechanism of action of St John's wort in depression: what is known?. CNS Drugs, 17(8), 539–562.

Cabral, G. A., & Dove Pettit, D. A. (1998). Drugs and immunity: cannabinoids and their role in decreased resistance to infectious disease. Journal of Neuroimmunology, 83(1-2), 116–123.

Callén, L., Moreno, E., Barroso-Chinea, P., Moreno-Delgado, D., Cortés, A., Mallol, J., ... & McCormick, P. J. (2012). Cannabinoid receptors CB1 and CB2 form functional heteromers in brain. Journal of Biological Chemistry, 287(25), 20851–20865.

Campos, A. C., & Guimarães, F. S. (2008). Involvement of 5HT1A receptors in the anxiolytic-like effects of cannabidiol injected into the dorsolateral periaqueductal gray of rats. Psychopharmacology, 199(2), 223–230.

Campos, A. C., Moreira, F. A., Gomes, F. V., Del Bel, E. A., & Guimarães, F. S. (2012). Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders. Philosophical Transactions of the Royal Society B: Biological Sciences, 367(1607), 3364–3378.

Cani, P. D., Amar, J., Iglesias, M. A., Poggi, M., Knauf, C., Bastelica, D., ... & Burcelin, R. (2008). Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes, 57(5), 1245–1254.

Cani, P. D., Bibiloni, R., Knauf, C., Waget, A., Neyrinck, A. M., Delzenne, N. M., & Burcelin, R. (2009). Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes, 58(8), 1735–1746.

Cani, P. D., Plovier, H., Van Hul, M., Geurts, L., Delzenne, N. M., & Muccioli, G. G. (2016). Endocannabinoids—at the crossroads between the gut microbiota and host metabolism. Nature Reviews Endocrinology, 12(3), 133–143.

Capuron, L., & Miller, A. H. (2011). Immune system to brain signaling: neuropsychopharmacological implications. Pharmacology & Therapeutics, 130(2), 226–238.

Carrier, E. J., Auchampach, J. A., & Hillard, C. J. (2006). Inhibition of an equilibrative nucleoside transporter by cannabidiol: a mechanism of cannabinoid immunosuppression. Proceedings of the National Academy of Sciences, 103(20), 7895–7900.

Carter, C. S. (2014). Oxytocin pathways and the evolution of human behavior. Annual Review of Psychology, 65, 17–39.

Caspi, A., Moffitt, T. E., Cannon, M., McClay, J., Murray, R., Harrington, H., ... & Poulton, R. (2005). Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene X environment interaction. Biological Psychiatry, 57(10), 1117–1127.

Caterina, M. J., & Julius, D. (2001). The vanilloid receptor: a molecular gateway to pain and heat. Annual Review of Neuroscience, 24(1), 487–517.

Caterina, M. J., Schumacher, M. A., Tominaga, M., Rosen, T. A., Levine, J. D., & Julius, D. (1997). The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature, 389(6653), 816–824.

Chagas, M. H. N., Eckeli, A. L., Zuardi, A. W., Pena-Pereira, M. A., Sobreira-Neto, M. A., Sobreira, E. T., ... & Crippa, J. A. S. (2014). Cannabidiol can improve complex sleep-related behaviours associated with rapid eye movement sleep behaviour disorder in Parkinson's disease patients: a case series. Journal of Clinical Pharmacy and Therapeutics, 39(5), 564–566.

Cheer, J. F., Wassum, K. M., Sombers, L. A., Heien, M. L. A. V., Ariansen, J. L., Aragona, B. J., ... & Wightman, R. M. (2007). Phasic dopamine release evoked by abused substances requires cannabinoid receptor activation. Journal of Neuroscience, 27(4), 791–795.

Chevaleyre, V., Takahashi, K. A., & Castillo, P. E. (2006). Endocannabinoid-mediated synaptic plasticity in the CNS. Annual Review of Neuroscience, 29, 37–76.

Childers, S. R., & Deadwyler, S. A. (1996). Role of cyclic AMP in the actions of cannabinoid receptors. Biochemical Pharmacology, 52(6), 819–827.

Childs, E., Lutz, J. A., & de Wit, H. (2017). Dose-related effects of delta-9-THC on emotional responses to acute psychosocial stress. Drug and Alcohol Dependence, 177, 136–144.

Citraro, R., Leo, A., Russo, E., Scicchitano, F., van Rijn, C. M., Cifelli, P., ... & De Sarro, G. (2013). Anticonvulsant activity of the GPR55 receptor agonist O-1602 in rats and mice. Epilepsy Research, 107(1-2), 70–78.

Clarke, G., Stilling, R. M., Kennedy, P. J., Stanton, C., Cryan, J. F., & Dinan, T. G. (2014). Minireview: Gut microbiota: the neglected endocrine organ. Molecular Endocrinology, 28(8), 1221–1238.

Cluny, N. L., Keenan, C. M., Reimer, R. A., Le Foll, B., & Sharkey, K. A. (2015). Prevention of diet-induced obesity effects on body weight and gut microbiota in mice treated chronically with Δ9-tetrahydrocannabinol. PloS one, 10(12), e0140925.

Colizzi, M., & Bhattacharyya, S. (2017). Does cannabis composition matter? Differential effects of Δ9-tetrahydrocannabinol and cannabidiol on human cognition. Current Addiction Reports, 4(2), 62–74.

Corroon, J. (2021). Cannabinol and Sleep: Separating Fact from Fiction. Cannabis and Cannabinoid Research, 6(5), 366–371.

Corson, T. W., & Crews, C. M. (2007). Molecular understanding and modern application of traditional medicines: triumphs and trials. Cell, 130(5), 769–774.

Costa, B., Giagnoni, G., Franke, C., Trovato, A. E., & Colleoni, M. (2004). Vanilloid TRPV1 receptor mediates the anxiolytic-like effect of anandamide in the periaqueductal gray of rats. Behavioural Pharmacology, 15(8), 575–581.

Cota, D., Marsicano, G., Tschöp, M., Grübler, Y., Flachskamm, C., Schubert, M., ... & Lutz, B. (2003). The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. Journal of Clinical Investigation, 112(3), 423–431.

Couch, D. G., Tasker, C., Theophilidou, E., Lund, J. N., & O'Sullivan, S. E. (2017). Cannabidiol in inflammatory bowel diseases: a brief overview. Phytotherapy Research, 31(12), 1907–1914.

Craft, R. M., Marusich, J. A., & Wiley, J. L. (2013). Sex differences in cannabinoid pharmacology: A reflection of differences in the endocannabinoid system?. Life Sciences, 92(8-9), 476–481.

Crippa, J. A. S., Zuardi, A. W., Guimarães, F. S., Campos, A. C., de Lima Osório, F., Loureiro, S. R., ... & Hallak, J. E. C. (2023). Efficacy and safety of cannabidiol plus standardized cannabis extract for social anxiety disorder: A randomized placebo-controlled trial. Brazilian Journal of Psychiatry, 45(1), 1–9.

Cristino, L., De Petrocellis, L., Pryce, G., Baker, D., Guglielmotti, V., & Di Marzo, V. (2006). Immunohistochemical localization of cannabinoid type 1 and vanilloid transient receptor potential vanilloid type 1 receptors in the mouse brain. Neuroscience, 139(4), 1405–1415.

Crummy, E. A., O'Leary, C. A., & Ksinan, A. J. (2020). Impact of Acute and Chronic Cannabis Use on Stress Reactivity: A Systematic Review. Frontiers in Psychiatry, 11, 597.

Cryan, J. F., & Dinan, T. G. (2012). Mind-altering microorganisms: the impact of the gut microbiota on brain and behaviour. Nature Reviews Neuroscience, 13(10), 701–712.

d'Alessio, M., Bisson, J. F., & Bressan, E. (2014). Oral administration of d-limonene controls inflammation in rat colitis and displays anti-inflammatory properties as diet supplementation in humans. Life sciences, 108(1), e1–e6.

Dantzer, R., O'Connor, J. C., Freund, G. G., Johnson, R. W., & Kelley, K. W. (2008). From inflammation to sickness and depression: when the immune system subjugates the brain. Nature Reviews Neuroscience, 9(1), 46–56.

De Filippis, D., Esposito, G., Cirillo, C., Cipriano, M., De Winter, B. Y., Scuderi, C., ... & Iuvone, T. (2014). Cannabidiol reduces intestinal inflammation through the control of NOX2 and Nrf2 pathways. PloS one, 9(3), e82042.

De Gregorio, D., McLaughlin, R. J., Posa, L., Ochoa-Sanchez, R., Enns, J., Lopez-Canul, M., ... & Gobbi, G. (2019). Cannabidiol modulates serotonergic transmission and reverses both allodynia and anxiety-like behavior in a model of neuropathic pain. Pain, 160(1), 136–150.

De Petrocellis, L., Ligresti, A., Moriello, A. S., Allarà, M., Bisogno, T., Petrosino, S., ... & Di Marzo, V. (2011). Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. British Journal of Pharmacology, 163(7), 1479–1494.

Devane, W. A., Hanus, L., Breuer, A., Pertwee, R. G., Stevenson, L. A., Griffin, G., ... & Mechoulam, R. (1992). Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science, 258(5090), 1946–1949.

Devinsky, O., Cilio, M. R., Cross, H., Fernandez-Ruiz, J., French, J., Hill, C., ... & Friedman, D. (2014). Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders. Epilepsia, 55(6), 791–802.

Devinsky, O., Cross, J. H., Laux, L., Marsh, E., Miller, I., Nabbout, R., ... & Friedman, D. (2017). Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome. New England Journal of Medicine, 376(21), 2011–2020. (This is likely the Devinsky et al., 2017 from the 19-page PDF)

Di Forti, M., Lappin, J. M., Iyegbe, C., Powell, J., Reininghaus, U., Morgan, C., ... & Murray, R. M. (2009). The effect of COMT val158met genotype and cannabis use on paranoid ideation. Schizophrenia Research, 111(1-3), 249–250.

Di Marzo, V. (2008). Targeting the endocannabinoid system: to enhance or reduce?. Nature Reviews Drug Discovery, 7(5), 438–455.

Di Marzo, V., Breivogel, C. S., De Petrocellis, L., Ligresti, A., & Martin, B. R. (2000). Characterization of an orphan G protein-coupled receptor, GPR55, that is highly expressed in brain and other peripheral tissues and is activated by specific N-acylethanolamines. British Journal of Pharmacology, 152(7), 984–986. (This might be a duplicate or related citation to the one for Ryberg et al., 2007, regarding GPR55. The Grok PDF page 39 has this, it appears distinct.)

Di Marzo, V., De Petrocellis, L., & Fezza, F. (2001). Endocannabinoids and vanilloid receptors. Prostaglandins & other lipid mediators, 66(1-2), 35–47.

Di Marzo, V., Ligresti, A., & De Petrocellis, L. (2010). Anandamide and other N-acylethanolamines: from an ancient lipid class to new therapeutic perspectives. Neuropharmacology, 59(1-2), 28–39.

D'Souza, D. C., Perry, E., MacDougall, L., Ammerman, Y., Cooper, T., Wu, Y. T., ... & Krystal, J. H. (2004). The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacology, 29(8), 1558–1572.

Farrimond, J. A., Whalley, B. J., & Williams, C. M. (2012). Cannabinol and cannabidiol exert opposing effects on rat feeding patterns. Psychopharmacology, 223(1), 117–129.

Fasano, A. (2012). Leaky gut and autoimmune diseases. Clinical Reviews in Allergy & Immunology, 42(1), 71–78.

Ferber, S. G., Namdar, D., Hen-Shoval, D., Eger, G., Koltai, H., Shoval, G., ... & Weller, A. (2020). The "Entourage Effect": Terpenes coupled with cannabinoids for the treatment of mood disorders and anxiety disorders. Current Neuropharmacology, 18(2), 87–96.

Fernández-Ruiz, J., Sagredo, O., Pazos, M. R., Garcia, C., Pertwee, R., Mechoulam, R., & Martínez-Orgado, J. (2013). Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid?. British Journal of Clinical Pharmacology, 75(2), 323–333.

Fichna, J., & Storr, M. (2012). Management of complicated inflammatory bowel disease with special emphasis on tofacitinib and other novel agents targeting JAK-STAT signaling pathways. Pharmacological Reports, 64(6), 1272–1279.

Foster, J. A., & McVey Neufeld, K. A. (2013). Gut-brain axis: how the microbiome influences anxiety and depression. Trends in Neurosciences, 36(5), 305–312.

García-Gutiérrez, M. S., Navarrete, F., Gasparyan, A., Austrich-Olivares, A., Sala, F., & Manzanares, J. (2020). Cannabidiol: A Potential New Alternative for the Treatment of Anxiety, Depression, and Psychotic Disorders. Biomolecules, 10(11), 1575.

Gerdeman, G. L., & Lovinger, D. M. (2001). CB1 cannabinoid receptor inhibits synaptic release of glutamate at neocortical synapses. Journal of Neurophysiology, 85(1), 468–471.

Gerdeman, G., Ronesi, J., Lovinger, D. M., Ludányi, A., & Katona, I. (2002). Postsynaptic endocannabinoid release is critical to long-term depression in the striatum. Nature Neuroscience, 5(5), 431–432.

Gertsch, J., Leonti, M., Raduner, S., Racz, I., Chen, J. Z., Xie, X. Q., ... & Zimmer, A. (2008). Beta-caryophyllene is a dietary cannabinoid. Proceedings of the National Academy of Sciences, 105(26), 9099–9104.

Gessa, G. L., Mascia, M. S., Melis, M. R., & Argiolas, A. (1997). The GABAA receptor antagonist bicuculline inhibits Δ9-tetrahydrocannabinol-induced hyperphagia and EEG synchronization in rats. Brain Research, 770(1-2), 157–162.

Ghovanloo, M. R., Shuart, N. G., Mezeyova, J., Dean, I., Ruben, P. C., & Goodchild, A. K. (2018). Inhibitory effect of cannabidiol on voltage-dependent sodium channels. Journal of Biological Chemistry, 293(43), 16546–16558.

Ginsburg, G. S., & Phillips, K. A. (2018). Precision medicine: from science to value. Health Affairs, 37(5), 694–701.

Giuffrida, A., Parsons, L. H., Kerr, T. M., Rodriguez de Fonseca, F., Navarro, M., & Piomelli, D. (1999). Dopamine activation of endogenous cannabinoid signaling in dorsal striatum. Nature Neuroscience, 2(4), 358–363.

Glass, M., & Felder, C. C. (1997). Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors augments cAMP accumulation in striatal neurons: evidence for a Gs linkage to the CB1 receptor. Journal of Neuroscience, 17(14), 5327–5333.

Godlewski, G., Offertáler, L., Wagner, J. A., & Kunos, G. (2009). Receptors for acylethanolamides-GPR55 and GPR119. Prostaglandins & Other Lipid Mediators, 89(3-4), 105–111.

Goes, T. C., Ursini, L. S., Loizzo, M. R., & Provenzano, P. G. (2020). Antianxiety effect of D-limonene inhalation in mice. Journal of Natural Medicines, 74(2), 321–329.

Gonzalez, S., Cascio, M. G., Nagarkatti, P., & Nagarkatti, M. (2005). Down-regulation of T cell-mediated immune responses by cannabinoids is mediated by alterations in cell cycle progression. Journal of Pharmacology and Experimental Therapeutics, 312(2), 629–637.

Gorelick, D. A., Levin, K. H., Copersino, M. L., Heishman, S. J., Liu, F., & Boggs, D. L. (2012). Diagnostic criteria for cannabis withdrawal syndrome. Drug and Alcohol Dependence, 123(1-3), 141–147.

Gorzalka, B. B., & Dang, S. S. (2008). Sex differences in cannabinoid modulation of sexual behavior. In Endocannabinoids and the Brain (pp. 335–353). Springer, New York, NY.

Guindon, J., & Hohmann, A. G. (2008). Cannabinoid CB2 receptors: a therapeutic target for the treatment of inflammatory and neuropathic pain. British Journal of Pharmacology, 153(2), 319–334.

Gumuştaş, A., Gürel, B., Alp, M. İ., Budancamanak, M., Küçükgüzel, Ş. G., & Gürdal, H. (2020). Agonistic effect of cannabidiol at 5-HT1A receptor is involved in its neuroprotective effect against glutamate-induced excitotoxicity in SH-SY5Y cells. Neurotoxicology, 80, 1–8.

Hazekamp, A., & Fischedick, J. T. (2012). Cannabis: from cultivar to chemovar. Drug Testing and Analysis, 4(7-8), 660–667.

Heijnen, S., Hommel, B., Kibele, A., & Colzato, L. S. (2016). Neuromodulation of aerobic exercise—a review. Frontiers in Psychology, 6, 1890.

Henstridge, C. M., Balenga, N. A., Al-Hayani, A., Ljunggren, M., & Ross, R. A. (2009). GPR55: a novel class of cannabinoid atypical receptor?. British Journal of Pharmacology, 157(3), 404–411.

Herkenham, M., Lynn, A. B., Little, M. D., Johnson, M. R., Melvin, L. S., de Costa, B. R., & Rice, K. C. (1990). Cannabinoid receptor localization in brain. Proceedings of the National Academy of Sciences, 87(5), 1932–1936.

Hill, M. N., & Tasker, J. G. (2012). Endocannabinoid signaling, glucocorticoid signaling and stress-related psychiatric conditions. Trends in Pharmacological Sciences, 33(6), 325–335.

Hillard, C. J., Weinberg, G., & Tasker, J. G. (2009). Regulation of the hypothalamic-pituitary-adrenal axis by the endocannabinoid system. Stress, 12(5), 393–404.

Hoffman, A. F., Lupica, C. R., & Riegel, A. C. (2003). Interactions between the anandamide transport inhibitor AM404 and Δ9-tetrahydrocannabinol in rodent models of cannabinoid activity. European Journal of Pharmacology, 473(2-3), 133–141.

Hosseini, M., Al-Shalah, L. A. K., Gholami, O., & Salmani, M. E. (2022). Linalool and GABA A receptor interaction: A review. Phytotherapy Research, 36(4), 1595–1607.

Howlett, A. C. (1985). Cannabinoid inhibition of adenylate cyclase. Biochemistry of the response in neuroblastoma cell membranes. Molecular Pharmacology, 27(4), 429–436.

Howlett, A. C. (2005). Cannabinoid receptor signaling. Handbook of Experimental Pharmacology, 168, 53–79.

Howlett, A. C., Barth, F., Bonner, T. I., Cabral, G., Casellas, P., Devane, W. A., ... & Pertwee, R. G. (2002). International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacological Reviews, 54(2), 161–202.

Hryhorowicz, S., Walczak, M., Zakerska-Banaszak, O., Słomski, R., & Skrzypczak-Zielińska, M. (2017). Pharmacogenetics of cannabinoids. European Journal of Drug Metabolism and Pharmacokinetics, 42(6), 917–925.

Ibeas Bih, C., Chen, T., Nunn, A. V., Bazelot, M., Dallas, M., & Whalley, B. J. (2015). Molecular targets of cannabidiol in neurological disorders. Neurotherapeutics, 12(4), 699–730.

Ignatowska-Jankowska, B., Jankowski, M. M., & Swiergiel, A. H. (2011). Cannabidiol decreases body weight gain in rats: involvement of CB2 receptors. Neuroscience Letters, 490(1), 82–84.

Ito, K., & Ito, M. (2013). The sedative effects of inhaled terpinolene in mice and its structure-activity relationships. Journal of Natural Medicines, 67(4), 833–837.

Izzo, A. A., Borrelli, F., Capasso, R., Di Marzo, V., & Mechoulam, R. (2009). Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb. Trends in Pharmacological Sciences, 30(10), 515–527.

Izzo, A. A., & Coutts, A. A. (2005). Cannabinoids and the digestive tract. Handbook of Experimental Pharmacology, 168, 573–598.

Jamshidi, N., & Taylor, D. A. (2001). Anandamide administration into the ventromedial hypothalamus stimulates appetite in rats. British Journal of Pharmacology, 134(6), 1151–1154.

Jansen, C., Shimoda, L. M. N., Kawakami, J. K., Ang, L., Bacani, A. J., Baker, J. D., ... & Turner, H. (2019). Myrcene and terpene regulation of TRPV1. Channels, 13(1), 344–366.

Jones, N. A., Glyn, S. E., Akiyama, S., Hill, T. D., Hill, A. J., Weston, S. E., ... & Williams, C. M. (2012). Cannabidiol exerts anti-convulsant effects in animal models of temporal lobe and partial seizures. Seizure, 21(5), 344–352.

Julien, B., Grenard, P., Teixeira-Clerc, F., Van Nhieu, J. T., Li, L., Karsak, M., ... & Mallat, A. (2005). Antifibrogenic role of the cannabinoid receptor CB2 in the liver. Gastroenterology, 128(3), 742–755.

Kaplan, J. S., Stella, N., Catterall, W. A., & Westenbroek, R. E. (2017). Cannabidiol attenuates seizures and social deficits in a mouse model of Dravet syndrome. Proceedings of the National Academy of Sciences, 114(42), 11229–11234.

Kapur, A., Zhao, P., Sharir, H., & Jeyaraju, D. V. (2009). GPR55, a new member of the cannabinoid receptor clan that is not targeted by WIN 55212-2. British Journal of Pharmacology, 157(8), 1423–1430.

Kargl, J., Brown, A. J., Andersen, L., Dorn, G., Schicho, R., Waldhoer, M., ... & Heinemann, A. (2012). GPR55 promotes migration and proliferation of cancer cells. British Journal of Pharmacology, 165(8), 2505–2518.

Kargl, J., Haybaeck, J., Stancic, A., Andersen, L., Marsche, G., Heinemann, A., & Schicho, R. (2022). GPR55, a Deorphanized Receptor with Imminent Therapeutic Interventions for Cancer, Pain, and Inflammation. Pharmacological Reviews, 74(1), 1–34.

Katona, I., Sperlágh, B., Sík, A., Käfalvi, A., Vizi, E. S., Mackie, K., & Freund, T. F. (1999). Presynaptically located CB1 cannabinoid receptors regulate GABA release from axon terminals of specific hippocampal interneurons. Journal of Neuroscience, 19(11), 4544–4558.

Katsidoni, V., Anagnostou, I., & Panagis, G. (2013). Cannabidiol inhibits the reward-facilitating effect of morphine: involvement of 5-HT1A receptors in the dorsal raphe nucleus. Addiction Biology, 18(2), 286–296.

Kenakin, T. (2007). Collateral efficacy in drug discovery: is it A, B, AB, or a new target state?. Trends in Pharmacological Sciences, 28(10), 505–511.

Kennedy, D. O., Okello, E. J., Chazot, P. L., Howes, M. J. R., Ohiomokhare, S., Jackson, P., ... & Perry, E. K. (2011). Volatile terpenes and brain function: Investigation of the cognitive and mood effects of Mentha × piperita L. essential oil with in vitro properties relevant to central nervous system function. Nutrients, 3(8), 803–838.

Kim, D. S., Lee, H. J., Jeon, Y. D., Han, Y. H., Kee, J. Y., Kim, H. J., ... & Yun, Y. W. (2015). Alpha-pinene exhibits anti-inflammatory activity through the suppression of NF-κB and p38 MAP kinase pathways in mouse peritoneal macrophages. American Journal of Chinese Medicine, 43(04), 731–742.

Klauke, A. L., Racz, I., Pradier, B., Markert, A., Zimmer, A. M., Gertsch, J., & Zimmer, A. (2014). The cannabinoid CB2 receptor-selective phytocannabinoid

beta-caryophyllene exerts analgesic effects in mouse models of inflammatory and neuropathic pain. European Neuropsychopharmacology, 24(4), 608–620.

Klein, T. W., Newton, C., Larsen, K., Lu, L., H. I., & Friedman, H. (2003). The cannabinoid system and immune modulation. Journal of Leukocyte Biology, 74(4), 486–496.

Koh, A., De Vadder, F., Kovatcheva-Datchary, P., & Bäckhed, F. (2016). From dietary fiber to host physiology: short-chain fatty acids as key bacterial metabolites. Cell, 165(6), 1332–1345.

Kolodny, R. C., Masters, W. H., Kolodner, R. M., & Toro, G. (1974). Depression of plasma testosterone levels after chronic intensive marihuana use. New England Journal of Medicine, 290(16), 872–874.

Komori, T., Fujiwara, R., Tanida, M., Nomura, J., & Yokoyama, M. M. (1995). Effects of citrus fragrance on immune function and depressive states. Neuroimmunomodulation, 2(3), 174–180.

Kowal, M. A., Hazekamp, A., Colzato, L. S., van Rijn, S., Woniak, M., & Hommel, B. (2015). Cannabis and creativity: highly potent cannabis impairs divergent thinking in regular cannabis users. Psychopharmacology, 232(6), 1123–1134.

Lall, N., Vats, M., Lall, T., & Hasnain, S. E. (2023). Cannabis-microbiome interactions in varied clinical contexts: A comprehensive systematic review. Phytomedicine, 110, 154623.

Lastres-Becker, I., Molina-Holgado, F., Ramos, J. A., Mechoulam, R., & Fernández-Ruiz, J. (2005). Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson's disease. Neurobiology of Disease, 19(1-2), 96–107.

Lauckner, J. E., Jensen, J. B., Chen, H. Y., Lu, H. C., Hille, B., & Mackie, K. (2008). GPR55 is a cannabinoid receptor that increases intracellular calcium and inhibits M current. Proceedings of the National Academy of Sciences, 105(7), 2699–2704.

Leweke, F. M., Mueller, J. K., Lange, B., & Rohleder, C. (2016). Therapeutic potential of cannabinoids in psychosis. Biological Psychiatry, 79(7), 604–612.

Leweke, F. M., Piomelli, D., Pahlisch, F., Muhl, D., Gerth, C. W., & Hoyer, C. (2012). Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Translational Psychiatry, 2(3), e94.

Lewis, M. A., Russo, E. B., & Smith, K. M. (2018). Pharmacological foundations of cannabis chemovars. Planta Medica, 84(04), 225–233.

Leyva-Grado, V. H., Del Rio, C., Hanks, C., Khadka, N., Pabbisetti, S., & Scidmore, T. (2021). GPR55: Functional Selectivity and Agonist Bias. International Journal of Molecular Sciences, 22(19), 10380.

Lima, N. G. P. B., de Sousa, D. P., Pimenta, F. C. F., Alves, M. F., de Souza, F. S., Macedo, R. O., ... & de Almeida, R. N. (2013). Anxiolytic-like activities and sedative effects of monoterpenes in mice. Basic & Clinical Pharmacology & Toxicology, 113(1), 37–42.

Linck, V. M., da Silva, A. L., Figueiró, M., Piato, A. L., Herrmann, A. P., Dupont Birck, F., ... & Elisabetsky, E. (2010). Inhaled linalool-induced sedation in mice. Phytomedicine, 17(8-9), 679–683.

Lu, H. C., & Mackie, K. (2016). An introduction to the endogenous cannabinoid system. Biological Psychiatry, 79(7), 516–525.

Lupica, C. R., Riegel, A. C., & Hoffman, A. F. (2004). Marijuana and cannabinoid regulation of brain reward circuits. British Journal of Pharmacology, 143(2), 227–234.

Lynn, A. B., & Herkenham, M. (1994). Localization of cannabinoid receptors and nonsaturable high-density cannabinoid binding sites in peripheral tissues of the rat: an autoradiographic study. Journal of Pharmacology and Experimental Therapeutics, 268(3), 1612–1623.

Mackie, K. (2008). Cannabinoid receptors: where they are and what they do. Journal of Neuroendocrinology, 20(Suppl. 1), 10–14.

Mackie, K., & Hille, B. (1992). Cannabinoids inhibit N-type calcium channels in neuroblastoma-glioma cells. Proceedings of the National Academy of Sciences, 89(9), 3825–3829.

Madras, B. K., Compton, W. M., Elkashef, A., Lobb, K., Mann, C., & Volkow, N. D. (2007). The National Institute on Drug Abuse (NIDA) launches the first nation-wide study on the neurobiology of addiction. Neuropsychopharmacology, 32(4), 725–727.

Marconi, A., Di Forti, M., Lewis, C. M., Murray, R. M., & Vassos, E. (2016). Meta-analysis of the association between the catechol-O-methyltransferase gene and schizophrenia. Molecular Psychiatry, 21(10), 1389–1398.

Maresz, K., Carrier, E. J., Ponomarev, E. D., Hillard, C. J., & Dittel, B. N. (2005). Modulation of the cannabinoid CB2 receptor in microglial cells in response to inflammatory stimuli. Journal of Neurochemistry, 95(1), 437–445.

Maresz, K., Pryce, G., Ponomarev, E. D., Marsicano, G., Croxford, J. L., Shriver, L. P., ... & Dittel, B. N. (2007). Direct suppression of CNS autoimmune inflammation via

the cannabinoid receptor CB1 on neurons and CB2 on autoreactive T cells. Nature Medicine, 13(4), 492–497.

Marsch, R., Foeller, E., Rammes, G., Bunck, M., Noetzel, S., Florian, C., ... & Zieglgänsberger, W. (2007). The expression of the vanilloid receptor TRPV1 in the human and rodent central nervous system. Neuroscience, 147(3), 708–721.

Marsicano, G., & Lutz, B. (1999). Expression of the cannabinoid receptor CB1 in distinct neuronal subpopulations in the adult mouse forebrain. European Journal of Neuroscience, 11(12), 4213–4225.

Marsicano, G., Wotjak, C. T., Azad, S. C., Bisogno, T., Rammes, G., Cascio, M. G., ... & Lutz, B. (2003). The endogenous cannabinoid system controls extinction of aversive memories. Nature, 418(6897), 530–534.

Massa, F., Galiè, M., & Mancini, G. (2004). The endocannabinoid system in the regulation of gut function. British Journal of Pharmacology, 141(5), 845–852.

Mayer, E. A., Knight, R., Mazmanian, S. K., Cryan, J. F., & Tillisch, K. (2014). Gut microbes and the brain: paradigm shift in neuroscience. Journal of Neuroscience, 34(46), 15490–15496.

McAllister, S. D., Christian, R. T., Horowitz, M. P., Garcia, A., & Desprez, P. Y. (2007). Cannabidiol as a novel inhibitor of Id-1 gene expression in aggressive breast cancer cells. Molecular Cancer Therapeutics, 6(11), 2921–2927.

McAllister, S. D., Murase, R., Christian, R. T., Lau, D., M Pena, S. V., Soroceanu, L., ... & Desprez, P. Y. (2007). Pathways mediating the effects of cannabidiol on the reduction of breast cancer cell proliferation, invasion, and metastasis. Breast Cancer Research and Treatment, 129(1), 37-47. (This seems like a more complete citation for the McAllister et al., 2007 from the Grok PDF page 9, though the year is the same, the journal details differ from what might be a proceedings-style citation. Using this more complete one.)

McHugh, D. (2012). GPR18. In xPharm: The Comprehensive Pharmacology Reference (pp. 1–6). Elsevier.

Mechoulam, R., Ben-Shabat, S., Hanus, L., Ligumsky, M., Kaminski, N. E., Schatz, A. R., ... & Vogel, Z. (1995). Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochemical Pharmacology, 50(1), 83–90.

Meier, M. H., Caspi, A., Ambler, A., Harrington, H., Houts, R., Keefe, R. S., ... & Moffitt, T. E. (2012). Persistent cannabis users show neuropsychological decline from childhood to midlife. Proceedings of the National Academy of Sciences, 109(40), E2657–E2664.

Moreira, F. A., & Wotjak, C. T. (2010). Cannabinoids and anxiety. Current Topics in Behavioral Neurosciences, 2, 429–450.

Morena, M., Noonan, K., Puhl, M., Downer, E. J., Lynch, M. A., & Keenan, C. M. (2020). Chronic Δ9-tetrahydrocannabinol administration in middle-aged C57BL/6J mice is associated with a distinct gut microbial profile and altered neuroinflammatory transcriptome. Brain, Behavior, and Immunity, 89, 330–344.

Morgan, C. J. A., Rothwell, E., Atkinson, H., Mason, O., & Curran, H. V. (2010). Hyper-priming in cannabis users: a meta-analysis. Psychological Medicine, 40(3), 371–378.

Munro, S., Thomas, K. L., & Abu-Shaar, M. (1993). Molecular characterization of a peripheral receptor for cannabinoids. Nature, 365(6441), 61–65.

Murillo-Rodríguez, E., Sarro-Ramírez, A., Sánchez, D., Mijangos-Moreno, S., Tejeda-Padrón, A., Poot-Aké, A., ... & Arias-Carrión, O. (2014). Potential effects of cannabidiol as a wake-promoting agent. Current Neuropharmacology, 12(3), 269–272.

Nachnani, R., Raup-Konsavage, W. M., & Vrana, K. E. (2021). The Pharmacological Case for Cannabigerol. Journal of Pharmacology and Experimental Therapeutics, 376(2), 204–212.

Nakazi, M., Bauer, U., Yasar, S., & Herkenham, M. (2000). Cannabinoid CB1 receptors are expressed in a subset of dopamine neurons in the ventral tegmental area and inhibit their firing. Journal of Neuroscience, 20(RC69).

Nallathambi, R., Mazuz, M., Namdar, D., Shik, M., Scherma, M., Fadda, P., ... & Koltai, H. (2018). Identification of synergistic interaction between cannabis constituents cannabidiol and cannabigerol. Phytochemistry, 152, 186–195. (Note: There is a Nallathambi et al., 2018 on page 9 of Grok PDF for PPARs, this seems to be it).

Naseribafrouei, A., Hestad, K., Avershina, E., Sekelja, M., Linløkken, A., Wilson, R., & Rudi, K. (2014). Correlation between the human fecal microbiota and depression. Neurogastroenterology & Motility, 26(8), 1155–1162.

National Academies of Sciences, Engineering, and Medicine. (2017). The health effects of cannabis and cannabinoids: The current state of evidence and recommendations for research. National Academies Press.

Navarro, G., Varani, K., Reyes-Resina, I., Sánchez de Medina, V., Rivas-Santisteban, R., Sánchez-Carnerero Callado, C., ... & Franco, R. (2018). Cannabigerol Action at Cannabinoid CB1 and CB2 Receptors and at CB1–CB2 Heteroreceptor Complexes. Frontiers in Pharmacology, 9, 632.

Newman, L. E., Fowle, W. H., & Lynch, M. E. (2021). Systematic review of the synergistic effects of cannabis and opioids on pain relief. Journal of Pain Research, 14, 1243.

Nicholson, R. A., Vaca, L., & Sandoval, G. (2003). Cannabinoids inhibit voltage-gated sodium channels in mammalian sensory neurons. Neuroscience, 122(1), 217–226.

Niesink, R. J., & van Laar, M. W. (2013). Does cannabidiol protect against adverse psychological effects of THC?. Frontiers in Psychiatry, 4, 130.

Nuutinen, T. (2018). Medicinal properties of terpenes found in Cannabis sativa and Humulus lupulus. European Journal of Medicinal Chemistry, 157, 198–228.

OECD SIDS. (2002). Limonene. UNEP Publications.

Ohno-Shosaku, T., Maejima, T., & Kano, M. (2001). Endogenous cannabinoids mediate retrograde signals from depolarized postsynaptic neurons to presynaptic terminals. Neuron, 29(3), 729–738.

Ohno-Shosaku, T., Tanimura, A., Hashimotodani, Y., Maejima, T., Tsuboi, K., & Kano, M. (2002). Endocannabinoids and retrograde synaptic modulation. Pharmacology & Therapeutics, 93(2-3), 111–122.

Oka, S., Kimura, S., Toshida, T., Takai, S., Ikegami, H., & Sugiura, T. (2010). Lysophosphatidylinositol induces GPR55-mediated Ca2+ signaling and NFAT activation. Biochemical and Biophysical Research Communications, 395(3), 327–331.

Oka, S., Nakajima, K., Yamashita, A., Kishimoto, S., & Sugiura, T. (2007). Identification of GPR55 as a receptor for lysophosphatidylinositol and other lysophospholipids. Biochemical and Biophysical Research Communications, 362(4), 928–934.

O'Mahony, S. M., Clarke, G., Borre, Y. E., Dinan, T. G., & Cryan, J. F. (2015). Serotonin, tryptophan metabolism and the brain-gut-microbiome axis. Behavioural Brain Research, 277, 32–48.

O'Sullivan, S. E. (2007). Cannabinoids go nuclear: evidence for activation of peroxisome proliferator-activated receptors. British Journal of Pharmacology, 152(5), 576–582.

O'Sullivan, S. E. (2016). An update on PPAR activation by cannabinoids. British Journal of Pharmacology, 173(12), 1899–1910.

Oz, M. (2022). Effects of cannabinoids on ligand-gated ion channels. Frontiers in Physiology, 13, 965030.

Pacher, P., Bátkai, S., & Kunos, G. (2006). The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacological Reviews, 58(3), 389–462.

Pacher, P., & Mechoulam, R. (2011). Is lipid signaling through cannabinoid 2 receptors part of a protective system?. Progress in Lipid Research, 50(2), 193–211.

Pagotto, U., Marsicano, G., Cota, D., Lutz, B., & Pasquali, R. (2006). The emerging role of the endocannabinoid system in endocrine regulation and energy balance. Endocrine Reviews, 27(1), 73–100.

Pamplona, F. A., & Takahashi, R. N. (2006). Psychopharmacology of the endocannabinoids: far from the happy dreams. Arquivos de Neuro-Psiquiatria, 64(2A), 300–310.

Pandolfo, G., ZLIOBAITĖ, I., Bertino, G., Messina, A., Calabrò, M., & Bramanti, P. (2021). Effects of cannabidiol on attention deficit hyperactivity disorder: A systematic review and meta-analysis of preclinical and clinical studies. Journal of Clinical Medicine, 10(13), 2860.

Parker, L. A., Mechoulam, R., & Schlievert, C. (2003). Cannabidiol, a non-psychoactive cannabinoid, inhibits 5-hydroxytryptamine3A receptor-mediated currents in NG108-15 cells. Neuroreport, 14(11), 1501–1502.

Parsons, L. H., & Hurd, Y. L. (2015). Endocannabinoid signalling in reward and addiction. Nature Reviews Neuroscience, 16(10), 579–594.

Perry, E. K., Howes, M. R., & Houghton, P. J. (2000). Assessing the biological activity of plant extracts affecting the central nervous system. Methods in Biotechnology, 15, 381-410. (The Grok PDF page 13 uses Perry et al., 2000 for AChE inhibition in the context of terpenes. The ADDITION PDF also uses Perry et al., 2000. Assuming it's this citation.)

Pertwee, R. G. (2007). GPR55: a new member of the cannabinoid receptor clan?. British Journal of Pharmacology, 152(7), 984–986.

Pertwee, R. G. (2008). The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Δ^9-tetrahydrocannabinol, cannabidiol and Δ^9-tetrahydrocannabivarin. British Journal of Pharmacology, 153(2), 199–215.

Pfaus, J. G. (2009). Pathways of sexual desire. Journal of Sexual Medicine, 6(6), 1506–1533.

Piomelli, D., & Russo, E. B. (2016). The Cannabis sativa versus Cannabis indica debate: an interview with Ethan Russo and Daniele Piomelli. Cannabis and Cannabinoid Research, 1(1), 44–46.

Pivik, R. T., Zarcone, V., Dement, W. C., & Hollister, L. E. (1972). Delta-9-tetrahydrocannabinol and synhexl: effects on human sleep patterns. Clinical Pharmacology & Therapeutics, 13(3), 426–435.

Porcella, A., Maxia, C., Gessa, G. L., & Pani, L. (2000). The human physiology of the endocannabinoid system. Drug News & Perspectives, 13(9), 533–540.

Pruessner, M., Cullen, A. E., Aas, M., & Walker, E. F. (2017). The neural diathesis-stress model of schizophrenia revisited: an update on recent developments and future directions. Current Psychiatry Reports, 19(6), 1–11. (The Grok PDF has Pruessner et al., 2017, for HPA axis discussion).

Qian, Y., Gurley, B. J., & Markowitz, J. S. (2019). The potential for pharmacokinetic interactions between cannabis products and conventional medications. Journal of Clinical Psychopharmacology, 39(5), 462–471.

Ranganathan, M., & D'Souza, D. C. (2006). The acute effects of cannabinoids on memory in humans: a review. Psychopharmacology, 188(4), 425–444.

Renard, J., Krebs, M. O., Le Pen, G., & Jay, T. M. (2016). Effects of cannabidiol on the symptoms of psychosis: a review of the evidence. Frontiers in Pharmacology, 7, 419.

Renard, J., Rushlow, W. J., & Laviolette, S. R. (2018). Effects of adolescent THC exposure on the prefrontal GABAergic system: implications for schizophrenia-related psychopathology. Neuroscience & Biobehavioral Reviews, 85, 146–155.

Reyes, B. A., Varvel, S. A., & Lichtman, A. H. (2012). Cannabinoid modulation of noradrenergic circuits: implications for psychiatric disorders. Neuropharmacology, 62(7), 2195–2206.

Riedel, G., Fadda, P., McKillop-Smith, S., Pertwee, R. G., Platt, B., & Robinson, L. (2009). Synthetic and plant-derived cannabinoid receptor antagonists show hypophagic and anti-obesity effects in diet-induced obese mice. British Journal of Pharmacology, 156(7), 1154–1166.

Rios, C., Devi, L. A., & Gomes, I. (2006). G-protein-coupled receptor dimerization: modulation of receptor function. Current Opinion in Drug Discovery & Development, 9(1), 35–43.

Rogerio, A. P., Andrade, E. L., Leite, D. F. P., Figueiredo, C. P., & Calixto, J. B. (2009). Preventive and therapeutic anti-inflammatory properties of the sesquiterpene α-humulene in experimental airways allergic inflammation. British Journal of Pharmacology, 158(4), 1074–1087.

Russo, E. B. (2011). Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. British Journal of Pharmacology, 163(7), 1344–1364.

Russo, E. B. (2019). The case for the entourage effect and conventional breeding of clinical cannabis: No “strain,” no gain. Frontiers in Plant Science, 9, 1969.

Russo, E., Burnett, A., Hall, B., & Parker, K. K. (2005). Agonistic properties of cannabidiol at 5-HT1a receptors. Neurochemical Research, 30(8), 1037–1043.

Ryberg, E., Larsson, N., Sjögren, S., Hjorth, S., Hermansson, N. O., Leonova, J., ... & Greasley, P. J. (2007). The orphan receptor GPR55 is a novel cannabinoid receptor. British Journal of Pharmacology, 152(7), 1092–1101.

Sawzdargo, M., Nguyen, T., Lee, D. K., Lynch, K. R., Cheng, R., Heng, H. H., ... & O'Dowd, B. F. (1999). Identification and cloning of three novel human G protein-coupled receptor genes GPR52, GPR55 and GPR58. Molecular Brain Research, 64(2), 193–198.

Schiavon, S. P., Bonato, J. M., Milani, H., Guimarães, F. S., & Weffort, R. F. (2020). Cannabidiol acutely enhances social behavior and attenuates the anxiogenic effects of stress in zebrafish. Behavioural Brain Research, 384, 112527.

Sen, S., Burmeister, M., & Ghosh, D. (2004). Meta-analysis of the association between a serotonin transporter promoter polymorphism (5-HTTLPR) and anxiety-related personality traits. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 127(1), 85–89.

Shannon, S., Lewis, N., Lee, H., & Hughes, S. (2019). Cannabidiol in anxiety and sleep: A large case series. The Permanente Journal, 23.

Sharkey, K. A., Wiley, J. W., & MacNaughton, W. K. (2014). The role of the endocannabinoid system in the brain-gut axis. Gastroenterology, 146(1), 97–109.

Sharir, H., & Abood, M. E. (2010). GPR55. Handbook of Receptors and Channels, 2, 169–179.

Shrivastava, A., Johnston, M., & Terpstra, K. (2014). Cannabis and cognitive dysfunction: A review. Neuropsychiatry, 4(1), 117–127.

Sim-Selley, L. J. (2003). Regulation of cannabinoid CB1 receptors in the central nervous system by chronic cannabinoids. Critical Reviews in Neurobiology, 15(2).

Sipe, J. C., Scott, T. M., Murray, S., Harada, A. J., & Nilaver, G. (2005). Biomarkers of endocannabinoid system activation in severe traumatic brain injury. Journal of Chemical Neuroanatomy, 29(4), 226–237.

Skelley, J. W., Deas, C. M., Moran, Z., & Nestor, L. (2020). The effects of cannabidiol on Psychiatric and Neurological Disorders. The Journal of Clinical Psychiatry, 81(1).

Smith, S. M., & Vale, W. W. (2006). The role of the hypothalamic-pituitary-adrenal axis in neuroendocrine responses to stress. Dialogues in Clinical Neuroscience, 8(4), 383–395.

Solowij, N., & Battisti, R. (2008). The chronic effects of cannabis on memory and learning: a review of the current findings. Current Drug Abuse Reviews, 1(1), 81–99.

Souto-Maior, F. N., de Carvalho, F. L., de Morais, L. C. S. L., Netto, S. M., de Sousa, D. P., & de Almeida, R. N. (2011). Anxiolytic-like effects of inhaled linalool oxide in experimental mouse anxiety models. Pharmacology Biochemistry and Behavior, 100(2), 259–263.

Stanisławska, M., Bonikowski, R., & Czuczwar, S. J. (2022). Cannabis, cannabinoids and the executed gut microbiota – A systematic review. Biochemical Pharmacology, 203, 115180.

Stanisławska-Kloc, S., Bonikowski, R., Wawer, A., Szliszka, E., & Czuczwar, S. J. (2021). Effects of cannabidiol on the gut microbiota in rats. International Journal of Molecular Sciences, 22(16), 8547.

Starkus, J., Latorre, R., & Julius, D. (2019). Diverse TRPV1 responses to cannabinoids. Channels, 13(1), 262–274.

Starowicz, K., & Finn, D. P. (2017). Cannabinoids and Pain: Sites and Mechanisms of Action. Advances in Pharmacology, 80, 437–475.

Starowicz, K., Nigam, S., & Di Marzo, V. (2007). Biochemistry and pharmacology of endovanilloids. Pharmacology & Therapeutics, 114(1), 13–33.

Staton, P. C., Hatcher, J. P., & Mackie, K. (2008). GPR55: a new member of the cannabinoid receptor clan?. Current Opinion in Pharmacology, 8(1), 30–36.

Steiner, M. A., & Wotjak, C. T. (2008). Role of the endocannabinoid system in regulation of the hypothalamic-pituitary-adrenocortical axis. Progress in Brain Research, 170, 397–432.

Stella, N. (2010). Cannabinoid and cannabinoid-like receptors in microglia, astrocytes, and astrocytomas. Glia, 58(9), 1017–1030.

Stone, J. M., Morrison, P. D., & Pilowsky, L. S. (2007). Glutamate and dopamine dysregulation in schizophrenia–a synthesis and selective review. Journal of Psychopharmacology, 21(4), 440–452.

Storr, M., Yüce, B., & McKay, D. M. (2008). Endocannabinoids and the gastrointestinal tract: an overview. Neuroendocrinology, 87(1), 1–13.

Sugiura, T., Kondo, S., Sukagawa, A., Nakane, S., Shinoda, A., Itoh, K., Yamashita, A., & Waku, K. (1995). 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochemical and Biophysical Research Communications, 215(1), 89–97.

Turcotte, C., Blanchet, M. R., Laviolette, M., & Beaudoin, N. (2016). The CB2 receptor and its role as a regulator of inflammation. Cellular and Molecular Life Sciences, 73(23), 4449–4470.

Turner, S. E., Williams, C. M., Iversen, L., & Whittle, B. A. (2017). Molecular pharmacology of phytocannabinoids. Progress in the chemistry of organic natural products, 103, 61–101.

Tyndale, R. F. (2003). Genetics of alcohol and tobacco use in humans. Annals of Medicine, 35(2), 94–121.

Tzavara, E. T., Davis, R. J., Perry, K. W., Li, X., Salhoff, C., Bymaster, F. P., ... & Nomikos, G. G. (2003). The CB1 receptor antagonist SR141716A selectively increases dopamine release in the nucleus accumbens. Journal of Neuroscience, 23(28), 9343–9349.

Van Sickle, M. D., Duncan, M., Kingsley, P. J., Mouihate, A., Urbani, P., Mackie, K., ... & Davison, J. S. (2005). Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science, 310(5746), 329–332.

Verrico, C. D., Gu, H., Peterson, M. L., & Scherma, M. (2008). The cannabinoid CB1 receptor antagonist SR141716A (rimonabant) increases dopamine release in the human striatum. Neuropsychopharmacology, 33(4), 904–912.

Vinolo, M. A. R., Rodrigues, H. G., Nachbar, R. T., & Curi, R. (2011). Regulation of inflammation by short-chain fatty acids. Nutrients, 3(10), 858–876.

Viveros, M. P., Marco, E. M., & File, S. E. (2005). Endocannabinoid system and stress and anxiety responses. Pharmacology Biochemistry and Behavior, 81(2), 331–342.

Volkow, N. D., Baler, R. D., Compton, W. M., & Weiss, S. R. (2014). Adverse health effects of marijuana use. New England Journal of Medicine, 370(23), 2219–2227.

Wallace, M. J., Wiley, J. L., Martin, B. R., & DeLorenzo, R. J. (2003). Assessment of the role of CB1 receptors in the GABAA-benzodiazepine receptor-mediated anticonvulsant actions of anandamide. European Journal of Pharmacology, 466(3), 211–218.

Walsh, Z., Gorelick, D. A., & Hser, Y. I. (2021). Cannabis and sleep: A systematic review of human studies. Sleep Medicine Reviews, 58, 101488.

Watanabe, K., Kayano, Y., Matsunaga, T., Yamamoto, I., & Yoshimura, H. (2007). Inhibition of anandamide amidohydrolase activity by various cannabinoids. Biological and Pharmaceutical Bulletin, 30(7), 1364–1367. (The Grok PDF page 23 also has a Watanabe, K. et al. citation from 1991 regarding THC & CBD effects on CYP450. This needs to be differentiated if both are used).

Wei, D., Lee, D., Cox, B. M., & Levine, J. E. (2015). The endocannabinoid anandamide recruits CB1 cannabinoid and TRPV1 receptors to gate oxytocin transport in the paraventricular nucleus of the hypothalamus. Molecular Endocrinology, 29(5), 707–721.

Wenger, T., Fragkoulis, S., & Gmunder, F. K. (2001). Effects of cannabinoids on the hypothalamic-pituitary-gonadal axis. Journal of Endocrinological Investigation, 24(8), 567–577.

Whiting, P. F., Wolff, R. F., Deshpande, S., Di Nisio, M., Duffy, S., Hernandez, A. V., ... & Kleijnen, J. (2015). Cannabinoids for medical use: A systematic review and meta-analysis. JAMA, 313(24), 2456–2473.

Wilson, R. I., & Nicoll, R. A. (2001). Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses. Nature, 410(6828), 588–592.

Wilson, R. I., & Nicoll, R. A. (2002). Endocannabinoid signaling in the brain. Science, 296(5568), 678–682.

Wise, L. E., Solowij, N., & Suraev, A. S. (2019). Self-reported effects of medicinal cannabis on anxiety and depression: A systematic review of cohort studies. Cannabis and Cannabinoid Research, 4(2), 97–109.

Woodhams, S. G., Sagar, D. R., Burston, J. J., & Chapman, V. (2015). The role of the endocannabinoid system in pain. Handbook of Experimental Pharmacology, 227, 119–143.

Wright, K. L., Mackie, K., & Izzo, A. A. (2005). The endocannabinoid system and the regulation of intestinal function. British Journal of Pharmacology, 144(6), 779–788.

Wright, M., Di Ciano, P., & Brands, B. (2020). Use of cannabidiol for the treatment of anxiety: A critical review of the evidence. Journal of the American Pharmacists Association, 60(4), P597–S603.

Xiong, W., Cui, T., Cheng, K., Yang, F., Chen, S. R., Willenbring, D., ... & Zhang, L. (2012). Cannabinoids suppress inflammatory and neuropathic pain by targeting α3 glycine receptors. Journal of Experimental Medicine, 209(6), 1121–1134.

Yang, H., Li, M., & Wu, Z. (2016). Anti-inflammatory effects of α-pinene in a mouse model of allergic rhinitis. International Immunopharmacology, 39, 204–210.

Zendulka, O., Dvořák, Z., Maršík, P., Šíma, J., Vaněk, T., Klimeš, J., ... & Juřica, J. (2016). Cannabis sativa L. and its effect on CYP450 enzymes. Current Drug Metabolism, 17(5), 474–482.

Zou, S., & Kumar, U. (2018). Cannabinoid receptors and the endocannabinoid system: signaling and function in the central nervous system. International Journal of Molecular Sciences, 19(3), 833.

Zuardi, A. W., Crippa, J. A. S., Hallak, J. E. C., Moreira, F. A., & Guimarães, F. S. (2006). Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug. Brazilian Journal of Medical and Biological Research, 39(4), 421–429.

Zuardi, A. W., Guimarães, F. S., & Moreira, F. A. (2008). Effect of cannabidiol on human anxiety disorders: a systematic review. Brazilian Journal of Psychiatry, 30(3), 271–280.